PedAM

Pediatric Disease Annotations & Medicines


	hepatitis c

Disease ID	187
Disease	hepatitis c
Definition	INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally, and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.
Synonym	hepatitis c (disorder) hepatitis c [disease/finding] hepatitis c infection hepatitis c viral hepatitis non a non b hepatitis non-a non-b hepatitis non-a non-b (disorder) hepatitis nona nonb hepatitis viral c hepatitis, non-a, non-b hepatitis, viral, non-a, non-b, parenterally-transmitted nanbh non b hepatitis non-a, non-b hepatitis nona nonb hepatitis parenterally transmitted non a, non b hepatitis parenterally-transmitted non-a, non-b hepatitis pt nanbh pt-nanbh type c viral hepatitis unspecified viral hepatitis c unspecified viral hepatitis c nos viral hepatitis c viral hepatitis c (disorder) viral hepatitis type c viral hepatitis type c (disorder) viral hepatitis, non-a, non-b viral hepatitis, non-a, non-b (disorder) viral hepatitis, non-a, non-b -retired-
DOID	DOID:1883
UMLS	C0019196
MeSH	D006526
SNOMED-CT	SNOMEDCT_US_2016_09_01:50711007;SNOMEDCT_US_2016_09_01:186634008
Comorbidity	UMLS \| Disease \| Sentences' Count(Total Sentences:296) C0023890 \| cirrhosis \| 176 C0019204 \| hepatocellular carcinoma \| 124 C0023895 \| liver disease \| 89 C0023890 \| liver cirrhosis \| 61 C0019158 \| hepatitis \| 45 C0019163 \| hepatitis b \| 31 C0011570 \| depression \| 30 C0040034 \| thrombocytopenia \| 27 C0011847 \| diabetes \| 27 C0010403 \| cryoglobulinemia \| 23 C0042384 \| vasculitis \| 19 C0002871 \| anemia \| 15 C0022658 \| kidney disease \| 13 C0022658 \| renal disease \| 13 C0024299 \| lymphoma \| 13 C0039730 \| thalassemia \| 12 C0022661 \| chronic kidney disease \| 10 C0033860 \| psoriasis \| 10 C0042769 \| viral infection \| 10 C0011849 \| diabetes mellitus \| 9 C0023903 \| liver cancer \| 8 C0042769 \| virus infection \| 8 C0024314 \| lymphoproliferative disorder \| 8 C0040147 \| thyroiditis \| 8 C0020538 \| hypertension \| 8 C0023646 \| lichen planus \| 8 C0022661 \| end-stage renal disease \| 7 C0023895 \| liver diseases \| 7 C0442874 \| neuropathy \| 7 C0079731 \| b-cell lymphoma \| 7 C0019069 \| hemophilia \| 7 C0011860 \| type 2 diabetes \| 6 C0017658 \| glomerulonephritis \| 6 C0042721 \| viral hepatitis \| 6 C0019069 \| haemophilia \| 6 C0036202 \| sarcoidosis \| 6 C0027947 \| neutropenia \| 6 C0079744 \| diffuse large b-cell lymphoma \| 6 C0014867 \| esophageal varices \| 6 C0021831 \| bowel disease \| 5 C0014867 \| oesophageal varices \| 5 C0002871 \| anaemia \| 5 C0021390 \| inflammatory bowel disease \| 5 C0024314 \| lymphoproliferative disorders \| 5 C0022658 \| nephropathy \| 5 C0042345 \| varices \| 5 C0037317 \| sleep disturbance \| 5 C0011226 \| hepatitis d \| 4 C0037317 \| sleep disturbances \| 4 C0948265 \| metabolic syndrome \| 4 C0920350 \| autoimmune thyroiditis \| 4 C0033687 \| proteinuria \| 4 C0019204 \| hepatoma \| 4 C0035078 \| renal failure \| 4 C0241910 \| autoimmune hepatitis \| 4 C0020541 \| portal hypertension \| 4 C0036341 \| schizophrenia \| 4 C0011860 \| type 2 diabetes mellitus \| 3 C0003873 \| rheumatoid arthritis \| 3 C0040128 \| thyroid disease \| 3 C0010403 \| cryoglobulinaemia \| 3 C0023448 \| lymphocytic leukemia \| 3 C0002874 \| aplastic anemia \| 3 C0005283 \| beta thalassemia \| 3 C0004153 \| atherosclerosis \| 3 C0021053 \| immune disease \| 3 C0023434 \| chronic lymphocytic leukemia \| 3 C0035309 \| retinopathy \| 3 C0031036 \| polyarteritis nodosa \| 3 C0003864 \| arthritis \| 3 C0024305 \| non-hodgkin's lymphoma \| 3 C0034150 \| purpura \| 3 C0023418 \| leukemia \| 3 C0010068 \| coronary artery disease \| 3 C0018799 \| heart disease \| 3 C0029132 \| optic neuropathy \| 3 C0022661 \| end stage renal disease \| 3 C0017661 \| iga nephropathy \| 3 C0023890 \| hepatic cirrhosis \| 3 C0008370 \| cholestasis \| 3 C0019204 \| hepatocellular carcinomas \| 3 C0282193 \| iron overload \| 3 C0019829 \| hodgkin's lymphoma \| 3 C0024299 \| lymphomas \| 2 C0008312 \| biliary cirrhosis \| 2 C0018213 \| graves' disease \| 2 C0019212 \| hepatorenal syndrome \| 2 C0002878 \| hemolytic anemia \| 2 C0032285 \| pneumonitis \| 2 C0040128 \| thyroid disorders \| 2 C0011991 \| diarrhea \| 2 C0027726 \| nephrotic syndrome \| 2 C0004623 \| bacterial infection \| 2 C0037274 \| skin disorders \| 2 C0002880 \| autoimmune hemolytic anemia \| 2 C0206698 \| cholangiocarcinoma \| 2 C0031117 \| peripheral neuropathy \| 2 C0006142 \| breast cancer \| 2 C0019829 \| hodgkin lymphoma \| 2 C0032285 \| pneumoniae \| 2 C0042870 \| vitamin d defic \| 2 C0024305 \| non-hodgkin lymphoma \| 2 C0008372 \| intrahepatic cholestasis \| 2 C0235618 \| proliferative glomerulonephritis \| 2 C0042870 \| vitamin d deficiency \| 2 C0008312 \| primary biliary cirrhosis \| 2 C0272286 \| immune thrombocytopenia \| 2 C0028754 \| obesity \| 2 C0085436 \| cryptococcal meningitis \| 2 C0026975 \| myelitis \| 2 C0007113 \| rectal cancer \| 2 C0040053 \| thrombosis \| 2 C0032285 \| pneumonia \| 2 C0162429 \| malnutrition \| 2 C0003467 \| anxiety \| 2 C0017662 \| membranoproliferative glomerulonephritis \| 2 C0025289 \| meningitis \| 2 C0037274 \| skin disorder \| 2 C0011644 \| scleroderma \| 2 C0023895 \| hepatic disease \| 1 C0039446 \| telangiectasia \| 1 C1302401 \| colorectal adenoma \| 1 C0039128 \| syphilis \| 1 C0027051 \| myocardial infarct \| 1 C0409974 \| lupus erythematosus \| 1 C0034212 \| pyoderma \| 1 C0349632 \| splenic marginal zone lymphoma \| 1 C0028242 \| nocardiosis \| 1 C0011854 \| type 1 diabetes \| 1 C0021359 \| infertile \| 1 C0013502 \| echinococcosis \| 1 C0002895 \| sickle cell disease \| 1 C0006271 \| bronchiolitis \| 1 C0242350 \| erectile dysfunction \| 1 C0001175 \| acquired immune deficiency \| 1 C0004712 \| balo's concentric sclerosis \| 1 C0001621 \| adrenal disease \| 1 C0019204 \| hepatocarcinoma \| 1 C0162529 \| ischemic colitis \| 1 C0020532 \| hypersplenism \| 1 C0023895 \| liver disorder \| 1 C0023434 \| b cell chronic lymphocytic leukemia \| 1 C0018799 \| cardiac disorders \| 1 C0004623 \| bacterial infections \| 1 C0010346 \| crohn's disease \| 1 C0034065 \| pulmonary embolism \| 1 C0751878 \| central nervous system vasculitis \| 1 C0031154 \| peritonitis \| 1 C0235974 \| pancreatic cancer \| 1 C0023434 \| small lymphocytic lymphoma \| 1 C0041696 \| major depression \| 1 C0013473 \| eating disorder \| 1 C0022658 \| kidney diseases \| 1 C0030305 \| pancreatitis \| 1 C0035229 \| respiratory insufficiency \| 1 C0341052 \| chronic sialadenitis \| 1 C0037274 \| skin diseases \| 1 C0023903 \| liver tumor \| 1 C0036203 \| cutaneous sarcoid \| 1 C0034155 \| thrombotic thrombocytopenic purpura \| 1 C0016053 \| fibromyalgia \| 1 C0151295 \| mononeuritis multiplex \| 1 C0009319 \| colitis \| 1 C0334533 \| arteriovenous hemangioma \| 1 C0042900 \| vitiligo \| 1 C0021390 \| inflammatory bowel diseases \| 1 C0011860 \| type ii diabetes \| 1 C0238124 \| necrotizing fasciitis \| 1 C0037061 \| siderosis \| 1 C0243010 \| viral encephalitis \| 1 C0086543 \| cataract \| 1 C0041696 \| major depressive disorder \| 1 C0003509 \| aortitis \| 1 C0008311 \| cholangitis \| 1 C0152021 \| congenital heart disease \| 1 C0020479 \| apolipoprotein e deficiency \| 1 C0026769 \| multiple sclerosis \| 1 C0007570 \| celiac disease \| 1 C0018023 \| nodular goiter \| 1 C0014130 \| endocrinopathy \| 1 C0085253 \| adult onset still's disease \| 1 C1565489 \| renal insufficiency \| 1 C0032302 \| mycoplasma pneumonia \| 1 C0018213 \| grave's disease \| 1 C0497327 \| dementia \| 1 C0861772 \| metastatic rectal cancer \| 1 C0034902 \| pure red cell aplasia \| 1 C0677607 \| hashimoto thyroiditis \| 1 C0010414 \| cryptococcosis \| 1 C0020598 \| hypoglycemia \| 1 C0041296 \| tuberculosis \| 1 C1561644 \| chronic kidney disease (ckd) \| 1 C0014070 \| encephalomyelitis \| 1 C0023467 \| acute myeloid leukemia \| 1 C0270549 \| generalized anxiety disorder \| 1 C0000889 \| acanthosis nigricans \| 1 C0037274 \| dermatological disorder \| 1 C0036323 \| schistosomiasis \| 1 C0017160 \| gastroenteritis \| 1 C0027721 \| minimal change nephropathy \| 1 C0009241 \| cognitive disorders \| 1 C1262481 \| eosinophilic gastroenteritis \| 1 C1337035 \| xanthogranulomatous cholecystitis \| 1 C0015230 \| rash \| 1 C0027868 \| neuromuscular disease \| 1 C0242342 \| sheehan's syndrome \| 1 C0011881 \| diabetic nephropathy \| 1 C0011854 \| type i diabetes \| 1 C0026848 \| muscular diseases \| 1 C1333387 \| endocrine syndrome \| 1 C0027051 \| myocardial infarction \| 1 C0036203 \| cutaneous sarcoidosis \| 1 C0022658 \| renal diseases \| 1 C0007642 \| cellulitis \| 1 C0345905 \| intrahepatic cholangiocarcinoma \| 1 C0020456 \| hyperglycemia \| 1 C0001125 \| lactic acidosis \| 1 C0079731 \| b-cell lymphomas \| 1 C0679466 \| cognitive deficits \| 1 C0032453 \| relapsing polychondritis \| 1 C0019151 \| hepatic encephalopathy \| 1 C0033953 \| sexual dysfunction \| 1 C0001175 \| acquired immune deficiency syndrome \| 1 C0036420 \| localized scleroderma \| 1 C0085652 \| pyoderma gangrenosum \| 1 C0022573 \| keratoconjunctivitis \| 1 C0023434 \| lymphocytic lymphoma \| 1 C0014060 \| encephalitis c \| 1 C0027697 \| nephritis \| 1 C0037274 \| skin disease \| 1 C0025202 \| melanoma \| 1 C0242770 \| bronchiolitis obliterans organizing pneumonia \| 1 C0020676 \| hypothyroidism \| 1 C0001973 \| alcoholism \| 1 C0001418 \| adenocarcinoma \| 1 C0036416 \| scleritis \| 1 C0020550 \| hyperthyroidism \| 1 C0008350 \| gallstone \| 1 C0019163 \| hepatitis b infection \| 1 C0039730 \| thalassaemia \| 1 C1136085 \| monoclonal gammopathy \| 1 C0006309 \| brucellosis \| 1 C0023895 \| liver disorders \| 1 C0085293 \| hepatitis e \| 1 C0007137 \| squamous cell carcinoma \| 1 C0013418 \| abnormal labor \| 1 C0002726 \| amyloidosis \| 1 C0221765 \| chronic schizophrenia \| 1 C0403529 \| pulmonary-renal syndrome \| 1 C0677607 \| lymphocytic thyroiditis \| 1 C0014059 \| acute disseminated encephalomyelitis \| 1 C0018916 \| hemangioma \| 1 C0018021 \| goiter \| 1 C0027868 \| neuromuscular diseases \| 1 C0009402 \| colorectal cancer \| 1 C1510472 \| drug addiction \| 1 C0037274 \| dermatologic disease \| 1 C0022661 \| chronic renal failure \| 1 C0022104 \| irritable bowel syndrome \| 1 C0751711 \| anterior ischemic optic neuropathy \| 1 C0029106 \| opisthorchiasis \| 1 C0019147 \| hepatic coma \| 1 C0027873 \| neuromyelitis optica \| 1 C0024143 \| lupus nephritis \| 1 C1112746 \| hepatic lymphoma \| 1 C0040128 \| thyroid diseases \| 1 C0009763 \| conjunctivitis \| 1 C0281963 \| red cell aplasia \| 1 C0003872 \| psoriatic arthritis \| 1 C0014118 \| endocarditis \| 1 C0002895 \| sickle-cell anemia \| 1 C2700641 \| lymphoplasmacytic lymphoma \| 1 C0001824 \| agranulocytosis \| 1 C0023470 \| myeloid leukemia \| 1 C0025322 \| early menopause \| 1 C0859939 \| classic polyarteritis nodosa \| 1 C0019163 \| viral hepatitis b \| 1 C0003469 \| anxiety disorder \| 1 C0022104 \| irritable bowel \| 1 C0014038 \| encephalitis \| 1 C0040156 \| thyrotoxicosis \| 1 C0043092 \| wegener's granulomatosis \| 1 C0270922 \| demyelinating neuropathy \| 1 C0314719 \| dry eye \| 1 C0018801 \| heart failure \| 1 C0015645 \| fasciitis \| 1 C0036337 \| schizoaffective disorder \| 1 C0037274 \| dermatosis \| 1 C0020542 \| pulmonary hypertension \| 1 C0079731 \| b-cell non-hodgkin lymphoma \| 1 C0036421 \| systemic sclerosis \| 1 C0041948 \| uremia \| 1 C0001339 \| acute pancreatitis \| 1 C0042769 \| viral infections \| 1 C0019163 \| serum hepatitis \| 1 C0002895 \| sickle cell anemia \| 1
Curated Gene	Entrez_id \| Symbol \| Resource(Total Genes:15) IFNG \| 3458 \| CTD_human HFE \| 3077 \| CTD_human PTPRC \| 5788 \| CTD_human CCR5 \| 1234 \| CTD_human LPL \| 4023 \| CTD_human CD81 \| 975 \| CTD_human IFNA2 \| 3440 \| CTD_human CYP2A6 \| 1548 \| CTD_human LOX \| 4015 \| CTD_human OPRM1 \| 4988 \| CTD_human IFNL3 \| 282617 \| CTD_human LOXL2 \| 4017 \| CTD_human CYP3A4 \| 1576 \| CTD_human SCARB1 \| 949 \| CTD_human DDX58 \| 23586 \| CTD_human
Inferring Gene	Entrez_id \| Symbol \| Resource(Total Genes:82) 100 \| ADA \| infer 183 \| AGT \| infer 229 \| ALDOB \| infer 162 \| AP1B1 \| infer 348 \| APOE \| infer 656 \| BMP8B \| infer 23523 \| CABIN1 \| infer 6347 \| CCL2 \| infer 6352 \| CCL5 \| infer 729230 \| CCR2 \| infer 1232 \| CCR3 \| infer 1234 \| CCR5 \| infer 947 \| CD34 \| infer 920 \| CD4 \| infer 941 \| CD80 \| infer 975 \| CD81 \| infer 10332 \| CLEC4M \| infer 1493 \| CTLA4 \| infer 6387 \| CXCL12 \| infer 1950 \| EGF \| infer 1956 \| EGFR \| infer 5610 \| EIF2AK2 \| infer 2052 \| EPHX1 \| infer 355 \| FAS \| infer 356 \| FASLG \| infer 2267 \| FGL1 \| infer 9402 \| GRAP2 \| infer 3077 \| HFE \| infer 3105 \| HLA-A \| infer 3106 \| HLA-B \| infer 3107 \| HLA-C \| infer 3117 \| HLA-DQA1 \| infer 3119 \| HLA-DQB1 \| infer 3123 \| HLA-DRB1 \| infer 3125 \| HLA-DRB3 \| infer 3429 \| IFI27 \| infer 3454 \| IFNAR1 \| infer 3455 \| IFNAR2 \| infer 3458 \| IFNG \| infer 3459 \| IFNGR1 \| infer 3586 \| IL10 \| infer 3587 \| IL10RA \| infer 3593 \| IL12B \| infer 3594 \| IL12RB1 \| infer 3603 \| IL16 \| infer 8809 \| IL18R1 \| infer 29949 \| IL19 \| infer 3553 \| IL1B \| infer 9173 \| IL1RL1 \| infer 50604 \| IL20 \| infer 50616 \| IL22 \| infer 11009 \| IL24 \| infer 3560 \| IL2RB \| infer 3565 \| IL4 \| infer 3566 \| IL4R \| infer 3569 \| IL6 \| infer 3659 \| IRF1 \| infer 3690 \| ITGB3 \| infer 3802 \| KIR2DL1 \| infer 3803 \| KIR2DL2 \| infer 3804 \| KIR2DL3 \| infer 3949 \| LDLR \| infer 4049 \| LTA \| infer 4053 \| LTBP2 \| infer 4153 \| MBL2 \| infer 4353 \| MPO \| infer 4599 \| MX1 \| infer 4790 \| NFKB1 \| infer 4938 \| OAS1 \| infer 5617 \| PRL \| infer 26191 \| PTPN22 \| infer 391719 \| RPL19P8 \| infer 6556 \| SLC11A1 \| infer 6532 \| SLC6A4 \| infer 3431 \| SP110 \| infer 6776 \| STAT5A \| infer 6820 \| SULT2B1 \| infer 6891 \| TAP2 \| infer 7037 \| TFRC \| infer 7040 \| TGFB1 \| infer 7124 \| TNF \| infer 7132 \| TNFRSF1A \| infer
Text Mined Gene	Entrez_id \| Symbol \| Score \| Resource(Total Genes:419) 7132 \| TNFRSF1A \| DISEASES 30009 \| TBX21 \| DISEASES 7066 \| THPO \| DISEASES 11274 \| USP18 \| DISEASES 402055 \| SRRD \| DISEASES 3162 \| HMOX1 \| DISEASES 80339 \| PNPLA3 \| DISEASES 3002 \| GZMB \| DISEASES 3929 \| LBP \| DISEASES 54941 \| RNF125 \| DISEASES 51311 \| TLR8 \| DISEASES 2158 \| F9 \| DISEASES 7076 \| TIMP1 \| DISEASES 4313 \| MMP2 \| DISEASES 2137 \| EXTL3 \| DISEASES 7038 \| TG \| DISEASES 8797 \| TNFRSF10A \| DISEASES 56729 \| RETN \| DISEASES 2091 \| FBL \| DISEASES 7040 \| TGFB1 \| DISEASES 973 \| CD79A \| DISEASES 57817 \| HAMP \| DISEASES 3082 \| HGF \| DISEASES 10135 \| NAMPT \| DISEASES 7036 \| TFR2 \| DISEASES 6348 \| CCL3 \| DISEASES 1440 \| CSF3 \| DISEASES 1655 \| DDX5 \| DISEASES 6347 \| CCL2 \| DISEASES 6357 \| CCL13 \| DISEASES 952 \| CD38 \| DISEASES 3558 \| IL2 \| DISEASES 3732 \| CD82 \| DISEASES 345 \| APOC3 \| DISEASES 3587 \| IL10RA \| DISEASES 969 \| CD69 \| DISEASES 1594 \| CYP27B1 \| DISEASES 4940 \| OAS3 \| DISEASES 3458 \| IFNG \| DISEASES 2597 \| GAPDH \| DISEASES 3820 \| KLRB1 \| DISEASES 7287 \| TULP1 \| DISEASES 3565 \| IL4 \| DISEASES 3567 \| IL5 \| DISEASES 5610 \| EIF2AK2 \| DISEASES 338 \| APOB \| DISEASES 5657 \| PRTN3 \| DISEASES 11126 \| CD160 \| DISEASES 335 \| APOA1 \| DISEASES 6626 \| SNRPA \| DISEASES 10384 \| BTN3A3 \| DISEASES 3659 \| IRF1 \| DISEASES 79143 \| MBOAT7 \| DISEASES 7389 \| UROD \| DISEASES 1236 \| CCR7 \| DISEASES 7355 \| SLC35A2 \| DISEASES 10875 \| FGL2 \| DISEASES 2678 \| GGT1 \| DISEASES 84316 \| NAA38 \| DISEASES 8554 \| PIAS1 \| DISEASES 968 \| CD68 \| DISEASES 6351 \| CCL4 \| DISEASES 3630 \| INS \| DISEASES 64151 \| NCAPG \| DISEASES 79132 \| DHX58 \| DISEASES 6674 \| SPAG1 \| DISEASES 5894 \| RAF1 \| DISEASES 25943 \| C20orf194 \| DISEASES 26290 \| GALNT8 \| DISEASES 348 \| APOE \| DISEASES 55821 \| ALLC \| DISEASES 2056 \| EPO \| DISEASES 1571 \| CYP2E1 \| DISEASES 2161 \| F12 \| DISEASES 2538 \| G6PC \| DISEASES 8431 \| NR0B2 \| DISEASES 6737 \| TRIM21 \| DISEASES 29107 \| NXT1 \| DISEASES 1401 \| CRP \| DISEASES 1116 \| CHI3L1 \| DISEASES 3845 \| KRAS \| DISEASES 56154 \| TEX15 \| DISEASES 1965 \| EIF2S1 \| DISEASES 10599 \| SLCO1B1 \| DISEASES 8638 \| OASL \| DISEASES 1593 \| CYP27A1 \| DISEASES 9392 \| TGFBRAP1 \| DISEASES 11014 \| KDELR2 \| DISEASES 3569 \| IL6 \| DISEASES 570 \| BAAT \| DISEASES 5168 \| ENPP2 \| DISEASES 3442 \| IFNA5 \| DISEASES 971 \| CD72 \| DISEASES 7097 \| TLR2 \| DISEASES 9411 \| ARHGAP29 \| DISEASES 1559 \| CYP2C9 \| DISEASES 51163 \| DBR1 \| DISEASES 9360 \| PPIG \| DISEASES 30061 \| SLC40A1 \| DISEASES 28234 \| SLCO1B3 \| DISEASES 7450 \| VWF \| DISEASES 949 \| SCARB1 \| DISEASES 6532 \| SLC6A4 \| DISEASES 4591 \| TRIM37 \| DISEASES 3959 \| LGALS3BP \| DISEASES 23523 \| CABIN1 \| DISEASES 3552 \| IL1A \| DISEASES 3553 \| IL1B \| DISEASES 55717 \| WDR11 \| DISEASES 64135 \| IFIH1 \| DISEASES 975 \| CD81 \| DISEASES 8647 \| ABCB11 \| DISEASES 943 \| TNFRSF8 \| DISEASES 3299 \| HSF4 \| DISEASES 941 \| CD80 \| DISEASES 5709 \| PSMD3 \| DISEASES 6774 \| STAT3 \| DISEASES 7297 \| TYK2 \| DISEASES 3383 \| ICAM1 \| DISEASES 1390 \| CREM \| DISEASES 4547 \| MTTP \| DISEASES 1374 \| CPT1A \| DISEASES 5244 \| ABCB4 \| DISEASES 939 \| CD27 \| DISEASES 55090 \| MED9 \| DISEASES 432 \| ASGR1 \| DISEASES 7157 \| TP53 \| DISEASES 3454 \| IFNAR1 \| DISEASES 207 \| AKT1 \| DISEASES 55244 \| SLC47A1 \| DISEASES 83417 \| FCRL4 \| DISEASES 9515 \| STXBP5L \| DISEASES 167410 \| LIX1 \| DISEASES 90523 \| MLIP \| DISEASES 134864 \| TAAR1 \| DISEASES 3439 \| IFNA1 \| DISEASES 22897 \| CEP164 \| DISEASES 149986 \| LSM14B \| DISEASES 117153 \| MIA2 \| DISEASES 3606 \| IL18 \| DISEASES 7342 \| UBP1 \| DISEASES 7345 \| UCHL1 \| DISEASES 27163 \| NAAA \| DISEASES 5468 \| PPARG \| DISEASES 29881 \| NPC1L1 \| DISEASES 3588 \| IL10RB \| DISEASES 3460 \| IFNGR2 \| DISEASES 539 \| ATP5O \| DISEASES 10841 \| FTCD \| DISEASES 115653 \| KIR3DL3 \| DISEASES 9437 \| NCR1 \| DISEASES 643 \| CXCR5 \| DISEASES 729230 \| CCR2 \| DISEASES 1234 \| CCR5 \| DISEASES 3046 \| HBE1 \| DISEASES 114757 \| CYGB \| DISEASES 6352 \| CCL5 \| DISEASES 3856 \| KRT8 \| DISEASES 10197 \| PSME3 \| DISEASES 124801 \| LSM12 \| DISEASES 7412 \| VCAM1 \| DISEASES 2215 \| FCGR3B \| DISEASES 5966 \| REL \| DISEASES 27306 \| HPGDS \| DISEASES 10461 \| MERTK \| DISEASES 5798 \| PTPRN \| DISEASES 213 \| ALB \| DISEASES 1230 \| CCR1 \| DISEASES 3600 \| IL15 \| DISEASES 3673 \| ITGA2 \| DISEASES 9607 \| CARTPT \| DISEASES 7098 \| TLR3 \| DISEASES 1437 \| CSF2 \| DISEASES 168667 \| BMPER \| DISEASES 79841 \| AGBL2 \| DISEASES 3429 \| IFI27 \| DISEASES 51523 \| CXXC5 \| DISEASES 3479 \| IGF1 \| DISEASES 2357 \| FPR1 \| DISEASES 3603 \| IL16 \| DISEASES 54578 \| UGT1A6 \| DISEASES 29 \| ABR \| DISEASES 1493 \| CTLA4 \| DISEASES 171558 \| PTCRA \| DISEASES 54658 \| UGT1A1 \| DISEASES 3667 \| IRS1 \| DISEASES 3627 \| CXCL10 \| DISEASES 3575 \| IL7R \| DISEASES 3669 \| ISG20 \| DISEASES 6373 \| CXCL11 \| DISEASES 27087 \| B3GAT1 \| DISEASES 3159 \| HMGA1 \| DISEASES 2147 \| F2 \| DISEASES 9940 \| DLEC1 \| DISEASES 6868 \| ADAM17 \| DISEASES 3661 \| IRF3 \| DISEASES 27257 \| LSM1 \| DISEASES 836 \| CASP3 \| DISEASES 84868 \| HAVCR2 \| DISEASES 3952 \| LEP \| DISEASES 285 \| ANGPT2 \| DISEASES 9153 \| SLC28A2 \| DISEASES 30835 \| CD209 \| DISEASES 6773 \| STAT2 \| DISEASES 10859 \| LILRB1 \| DISEASES 9478 \| CABP1 \| DISEASES 144811 \| LACC1 \| DISEASES 4684 \| NCAM1 \| DISEASES 7173 \| TPO \| DISEASES 84967 \| LSM10 \| DISEASES 29851 \| ICOS \| DISEASES 9370 \| ADIPOQ \| DISEASES 3615 \| IMPDH2 \| DISEASES 6014 \| RIT2 \| DISEASES 4312 \| MMP1 \| DISEASES 2 \| A2M \| DISEASES 30832 \| ZNF354C \| DISEASES 5441 \| POLR2L \| DISEASES 22820 \| COPG1 \| DISEASES 79228 \| THOC6 \| DISEASES 146802 \| SLC47A2 \| DISEASES 3855 \| KRT7 \| DISEASES 3665 \| IRF7 \| DISEASES 8651 \| SOCS1 \| DISEASES 9021 \| SOCS3 \| DISEASES 8519 \| IFITM1 \| DISEASES 942 \| CD86 \| DISEASES 256933 \| NPB \| DISEASES 4088 \| SMAD3 \| DISEASES 3916 \| LAMP1 \| DISEASES 4600 \| MX2 \| DISEASES 55256 \| ADI1 \| DISEASES 3043 \| HBB \| DISEASES 120227 \| CYP2R1 \| DISEASES 5133 \| PDCD1 \| DISEASES 148738 \| HFE2 \| DISEASES 1576 \| CYP3A4 \| DISEASES 3824 \| KLRD1 \| DISEASES 3266 \| ERAS \| DISEASES 3117 \| HLA-DQA1 \| DISEASES 4306 \| NR3C2 \| DISEASES 54681 \| P4HTM \| DISEASES 1544 \| CYP1A2 \| DISEASES 145264 \| SERPINA12 \| DISEASES 259197 \| NCR3 \| DISEASES 3804 \| KIR2DL3 \| DISEASES 4939 \| OAS2 \| DISEASES 2537 \| IFI6 \| DISEASES 921 \| CD5 \| DISEASES 10811 \| NOXA1 \| DISEASES 6672 \| SP100 \| DISEASES 3716 \| JAK1 \| DISEASES 27068 \| PPA2 \| DISEASES 3455 \| IFNAR2 \| DISEASES 3605 \| IL17A \| DISEASES 26234 \| FBXL5 \| DISEASES 84706 \| GPT2 \| DISEASES 1861 \| TOR1A \| DISEASES 65992 \| DDRGK1 \| DISEASES 100506658 \| OCLN \| DISEASES 50488 \| MINK1 \| DISEASES 1717 \| DHCR7 \| DISEASES 355 \| FAS \| DISEASES 5265 \| SERPINA1 \| DISEASES 6720 \| SREBF1 \| DISEASES 3240 \| HP \| DISEASES 51155 \| HN1 \| DISEASES 11118 \| BTN3A2 \| DISEASES 5725 \| PTBP1 \| DISEASES 51161 \| C3orf18 \| DISEASES 8270 \| LAGE3 \| DISEASES 6714 \| SRC \| DISEASES 6775 \| STAT4 \| DISEASES 3821 \| KLRC1 \| DISEASES 9332 \| CD163 \| DISEASES 123096 \| SLC25A29 \| DISEASES 5094 \| PCBP2 \| DISEASES 57016 \| AKR1B10 \| DISEASES 3123 \| HLA-DRB1 \| DISEASES 7037 \| TFRC \| DISEASES 2157 \| F8 \| DISEASES 1803 \| DPP4 \| DISEASES 1565 \| CYP2D6 \| DISEASES 54106 \| TLR9 \| DISEASES 6772 \| STAT1 \| DISEASES 4283 \| CXCL9 \| DISEASES 3880 \| KRT19 \| DISEASES 58 \| ACTA1 \| DISEASES 2853 \| GPR31 \| DISEASES 5788 \| PTPRC \| DISEASES 6041 \| RNASEL \| DISEASES 356 \| FASLG \| DISEASES 3459 \| IFNGR1 \| DISEASES 2214 \| FCGR3A \| DISEASES 911 \| CD1C \| DISEASES 103 \| ADAR \| DISEASES 284486 \| THEM5 \| DISEASES 117247 \| SLC16A10 \| DISEASES 914 \| CD2 \| DISEASES 1268 \| CNR1 \| DISEASES 80143 \| SIKE1 \| DISEASES 1629 \| DBT \| DISEASES 959 \| CD40LG \| DISEASES 10561 \| IFI44 \| DISEASES 10964 \| IFI44L \| DISEASES 5950 \| RBP4 \| DISEASES 2030 \| SLC29A1 \| DISEASES 3434 \| IFIT1 \| DISEASES 958 \| CD40 \| DISEASES 4318 \| MMP9 \| DISEASES 4352 \| MPL \| DISEASES 1503 \| CTPS1 \| DISEASES 9436 \| NCR2 \| DISEASES 2833 \| CXCR3 \| DISEASES 1104 \| RCC1 \| DISEASES 7099 \| TLR4 \| DISEASES 23585 \| TMEM50A \| DISEASES 1269 \| CNR2 \| DISEASES 5698 \| PSMB9 \| DISEASES 5696 \| PSMB8 \| DISEASES 3118 \| HLA-DQA2 \| DISEASES 3127 \| HLA-DRB5 \| DISEASES 57819 \| LSM2 \| DISEASES 3055 \| HCK \| DISEASES 10673 \| TNFSF13B \| DISEASES 11330 \| CTRC \| DISEASES 50943 \| FOXP3 \| DISEASES 100507436 \| MICA \| DISEASES 3107 \| HLA-C \| DISEASES 64078 \| SLC28A3 \| DISEASES 7133 \| TNFRSF1B \| DISEASES 4524 \| MTHFR \| DISEASES 3133 \| HLA-E \| DISEASES 3105 \| HLA-A \| DISEASES 1471 \| CST3 \| DISEASES 8718 \| TNFRSF25 \| DISEASES 9308 \| CD83 \| DISEASES 9636 \| ISG15 \| DISEASES 2308 \| FOXO1 \| DISEASES 23586 \| DDX58 \| DISEASES 10346 \| TRIM22 \| DISEASES 3704 \| ITPA \| DISEASES 3440 \| IFNA2 \| DISEASES 3456 \| IFNB1 \| DISEASES 51284 \| TLR7 \| DISEASES 29126 \| CD274 \| DISEASES 10171 \| RCL1 \| DISEASES 3822 \| KLRC2 \| DISEASES 91543 \| RSAD2 \| DISEASES 51091 \| SEPSECS \| DISEASES 9681 \| DEPDC5 \| DISEASES 51280 \| GOLM1 \| DISEASES 3875 \| KRT18 \| DISEASES 53345 \| TM6SF2 \| DISEASES 28227 \| PPP2R3B \| DISEASES 3811 \| KIR3DL1 \| DISEASES 838 \| CASP5 \| DISEASES 3660 \| IRF2 \| DISEASES 55601 \| DDX60 \| DISEASES 5627 \| PROS1 \| DISEASES 9560 \| CCL4L2 \| DISEASES 6355 \| CCL8 \| DISEASES 4891 \| SLC11A2 \| DISEASES 6696 \| SPP1 \| DISEASES 3965 \| LGALS9 \| DISEASES 4239 \| MFAP4 \| DISEASES 174 \| AFP \| DISEASES 10379 \| IRF9 \| DISEASES 80380 \| PDCD1LG2 \| DISEASES 4599 \| MX1 \| DISEASES 1654 \| DDX3X \| DISEASES 3803 \| KIR2DL2 \| DISEASES 6654 \| SOS1 \| DISEASES 728441 \| GGT2 \| DISEASES 7018 \| TF \| DISEASES 1363 \| CPE \| DISEASES 4938 \| OAS1 \| DISEASES 55577 \| NAGK \| DISEASES 3113 \| HLA-DPA1 \| DISEASES 3447 \| IFNA13 \| DISEASES 3430 \| IFI35 \| DISEASES 720 \| C4A \| DISEASES 3702 \| ITK \| DISEASES 7124 \| TNF \| DISEASES 3106 \| HLA-B \| DISEASES 4615 \| MYD88 \| DISEASES 11319 \| ECD \| DISEASES 57506 \| MAVS \| DISEASES 4049 \| LTA \| DISEASES 388372 \| CCL4L1 \| DISEASES 3276 \| PRMT1 \| DISEASES 3115 \| HLA-DPB1 \| DISEASES 4050 \| LTB \| DISEASES 3451 \| IFNA17 \| DISEASES 3586 \| IL10 \| DISEASES 3441 \| IFNA4 \| DISEASES 3077 \| HFE \| DISEASES 338376 \| IFNE \| DISEASES 5515 \| PPP2CA \| DISEASES 5478 \| PPIA \| DISEASES 30816 \| ERVW-1 \| DISEASES 57541 \| ZNF398 \| DISEASES 2638 \| GC \| DISEASES 51428 \| DDX41 \| DISEASES 11075 \| STMN2 \| DISEASES 3620 \| IDO1 \| DISEASES 6207 \| RPS13 \| DISEASES 930 \| CD19 \| DISEASES 7421 \| VDR \| DISEASES 567 \| B2M \| DISEASES 11245 \| GPR176 \| DISEASES 3949 \| LDLR \| DISEASES 388588 \| SMIM1 \| DISEASES 284424 \| MIR7-3HG \| DISEASES 283902 \| HCCAT5 \| DISEASES 10866 \| HCP5 \| DISEASES 104326052 \| NRIR \| DISEASES 26800 \| SNORD49A \| DISEASES 101669766 \| ZNF350-AS1 \| DISEASES
Locus	(Waiting for update.)

Disease ID	187
Disease	hepatitis c
Integrated Phenotype	(Waiting for update.)
Text Mined Phenotype	HPO \| Name \| Sentences' Count(Total Phenotypes:175) HP:0001394 \| Hepatic cirrhosis \| 176 HP:0001402 \| Hepatocellular carcinoma \| 123 HP:0030731 \| Carcinoma \| 111 HP:0012115 \| Liver inflammation \| 51 HP:0001397 \| Hepatic steatosis \| 47 HP:0001395 \| Hepatic fibrosis \| 41 HP:0000855 \| Insulin resistance \| 34 HP:0000716 \| Depression \| 30 HP:0001873 \| Low platelet count \| 29 HP:0200123 \| Chronic liver inflammation \| 27 HP:0100778 \| Cryoglobulinemia \| 22 HP:0001903 \| Anemia \| 20 HP:0002633 \| Vasculitis \| 19 HP:0012378 \| Fatigue \| 16 HP:0002721 \| Immunodeficiency \| 13 HP:0002665 \| Lymphoma \| 13 HP:0003774 \| End-stage renal failure \| 11 HP:0001399 \| Liver failure \| 10 HP:0012622 \| Chronic kidney disease \| 10 HP:0003765 \| Psoriasis \| 10 HP:0000819 \| Diabetes mellitus \| 9 HP:0002896 \| Liver cancer \| 9 HP:0005523 \| Lymphoproliferative disorder \| 8 HP:0100646 \| Thyroiditis \| 8 HP:0000822 \| Hypertension \| 8 HP:0012191 \| B-cell lymphoma \| 7 HP:0006562 \| Viral hepatitis \| 6 HP:0001875 \| Neutropenia \| 6 HP:0000099 \| Glomerular nephritis \| 6 HP:0000952 \| Yellow skin \| 5 HP:0002716 \| Lymph node hyperplasia \| 5 HP:0000112 \| Nephropathy \| 5 HP:0002960 \| Autoimmune condition \| 5 HP:0002360 \| Sleep disturbance \| 5 HP:0012189 \| Hodgkin disease \| 5 HP:0000083 \| Renal insufficiency \| 5 HP:0000093 \| Proteinuria \| 4 HP:0001541 \| Ascites \| 4 HP:0001409 \| Portal hypertension \| 4 HP:0000820 \| Thyroid abnormality \| 3 HP:0005550 \| Chronic lymphatic leukemia \| 3 HP:0012531 \| Pain \| 3 HP:0000708 \| Behavioral problems \| 3 HP:0001369 \| Arthritis \| 3 HP:0100753 \| Schizophrenia \| 3 HP:0002621 \| Atherosclerosis \| 3 HP:0100543 \| Cognitive deficits \| 3 HP:0001138 \| Damaged optic nerve \| 3 HP:0000488 \| Noninflammatory retina disease \| 3 HP:0001396 \| Cholestasis \| 3 HP:0001677 \| Coronary artery disease \| 3 HP:0001915 \| Aplastic anemia \| 3 HP:0006515 \| Interstitial pneumonitis \| 3 HP:0001919 \| Acute renal failure \| 3 HP:0000979 \| Purpura \| 3 HP:0001909 \| Leukemia \| 3 HP:0010783 \| Erythema \| 3 HP:0002910 \| Elevated transaminases \| 2 HP:0001733 \| Pancreatic inflammation \| 2 HP:0004905 \| Vitamin A deficiency \| 2 HP:0001973 \| Autoimmune thrombocytopenia \| 2 HP:0012486 \| Inflammation of spinal cord \| 2 HP:0001370 \| Rheumatoid arthritis \| 2 HP:0012539 \| Non-Hodgkin lymphoma \| 2 HP:0001513 \| Obesity \| 2 HP:0002664 \| Neoplasia \| 2 HP:0002090 \| Pneumonia \| 2 HP:0001878 \| Haemolytic anaemia \| 2 HP:0006554 \| Acute hepatic failure \| 2 HP:0003002 \| Breast carcinoma \| 2 HP:0009830 \| Peripheral neuritis \| 2 HP:0001945 \| Fever \| 2 HP:0100324 \| Progressive systemic scleroderma \| 2 HP:0001824 \| Weight loss \| 2 HP:0011945 \| Cryptogenic organizing pneumonia \| 2 HP:0001404 \| Hepatocellular necrosis \| 2 HP:0002829 \| Arthralgias \| 2 HP:0001406 \| Intrahepatic cholestasis \| 2 HP:0004395 \| Malnutrition \| 2 HP:0000793 \| Membranoproliferative glomerulonephritis \| 2 HP:0001890 \| Autoimmune hemolytic anemia \| 2 HP:0002613 \| Biliary cirrhosis \| 2 HP:0001287 \| Meningitis \| 2 HP:0030153 \| Cholangiocarcinoma \| 2 HP:0000739 \| Anxiety \| 2 HP:0000100 \| Nephrosis \| 2 HP:0002014 \| Diarrhea \| 2 HP:0100512 \| Vitamin D deficiency \| 2 HP:0000217 \| Dry mouth syndrome \| 2 HP:0100280 \| Morbus Crohn \| 1 HP:0100820 \| Glomerulopathy \| 1 HP:0012532 \| Chronic pain \| 1 HP:0002383 \| Encephalitis \| 1 HP:0002894 \| Neoplasia of the pancreas \| 1 HP:0002013 \| Emesis \| 1 HP:0012234 \| Agranulocytosis \| 1 HP:0001943 \| Hypoglycemia \| 1 HP:0000505 \| Poor vision \| 1 HP:0012592 \| Albuminuria \| 1 HP:0100626 \| Chronic hepatic failure \| 1 HP:0002617 \| Aneurysmal dilatation \| 1 HP:0003073 \| Hypoalbuminaemia \| 1 HP:0002480 \| Hepatic encephalopathy \| 1 HP:0001735 \| Acute pancreatitis \| 1 HP:0004787 \| Fulminant hepatitis \| 1 HP:0000802 \| Erectile dysfunction \| 1 HP:0100584 \| Endocarditis \| 1 HP:0002955 \| Granulomatosis \| 1 HP:0100665 \| Angiooedema \| 1 HP:0012410 \| Pure red cell aplasia \| 1 HP:0001009 \| Telangiectases \| 1 HP:0011034 \| Amyloid disease \| 1 HP:0030151 \| Cholangitis \| 1 HP:0001028 \| Strawberry mark \| 1 HP:0002719 \| infections, recurrent \| 1 HP:0001907 \| Thromboembolic disease \| 1 HP:0000999 \| Pyoderma \| 1 HP:0005202 \| Helicobacter pylori infection \| 1 HP:0000956 \| Keratosis nigricans \| 1 HP:0000836 \| Overactive thyroid \| 1 HP:0000518 \| Cataract \| 1 HP:0002860 \| Squamous cell carcinoma \| 1 HP:0001045 \| Blotchy loss of skin color \| 1 HP:0002902 \| Hyponatremia \| 1 HP:0009027 \| Foot drop \| 1 HP:0000989 \| pruritis \| 1 HP:0002093 \| progressive respiratory failure \| 1 HP:0001880 \| Eosinophilia \| 1 HP:0010543 \| Opsoclonus \| 1 HP:0000726 \| Dementia \| 1 HP:0003074 \| High blood glucose \| 1 HP:0000853 \| Goitre \| 1 HP:0001336 \| Myoclonic jerks \| 1 HP:0004448 \| Fulminant hepatic failure \| 1 HP:0002092 \| Pulmonary artery hypertension \| 1 HP:0001250 \| Seizures \| 1 HP:0002861 \| Melanoma \| 1 HP:0002459 \| Dysautonomia \| 1 HP:0002586 \| Peritonitis \| 1 HP:0001410 \| Decreased liver function \| 1 HP:0009726 \| Renal neoplasm \| 1 HP:0003613 \| Antiphospholipid antibodies \| 1 HP:0000572 \| Visual loss \| 1 HP:0004943 \| Accelerated atherosclerosis \| 1 HP:0003281 \| Increased ferritin \| 1 HP:0011787 \| Central hypothyroidism \| 1 HP:0003077 \| Hyperlipidemia \| 1 HP:0005994 \| Nodular goiter \| 1 HP:0001300 \| Parkinsonism \| 1 HP:0012579 \| Minimal change glomerulonephritis \| 1 HP:0100805 \| Precocious menopause \| 1 HP:0011227 \| Elevated C-reactive protein level \| 1 HP:0001096 \| Keratoconjunctivitis \| 1 HP:0100532 \| Scleritis \| 1 HP:0001298 \| Encephalopathy \| 1 HP:0100658 \| Bacterial infection of skin \| 1 HP:0004808 \| Acute myelogenous leukemia \| 1 HP:0012324 \| Myeloid leukemia \| 1 HP:0001259 \| Coma \| 1 HP:0007417 \| Discoid lupus erythematosus \| 1 HP:0001971 \| Hypersplenism \| 1 HP:0011950 \| Bronchiolitis \| 1 HP:0002608 \| Celiac disease \| 1 HP:0000509 \| Conjunctivitis \| 1 HP:0100537 \| Inflammation of the fascia \| 1 HP:0001297 \| Cerebral vascular events \| 1 HP:0003128 \| Lactic acidosis \| 1 HP:0100827 \| Lymphocytosis \| 1 HP:0001941 \| acidemia \| 1 HP:0002583 \| Colitis \| 1 HP:0000821 \| Underactive thyroid \| 1 HP:0000872 \| Hashimoto's thyroiditis \| 1 HP:0001403 \| Macrovesicular steatosis \| 1 HP:0001658 \| Myocardial infarction \| 1 HP:0000123 \| Nephritis \| 1

Disease ID	187
Disease	hepatitis c
Manually Symptom	UMLS \| Name(Total Manually Symptoms:237) C2717757 \| susac syndrome C2711227 \| steatohepatitis C2711227 \| liver steatosis C2711227 \| hepatic steatosis C2707258 \| infections C2700470 \| inclusion body myositis C2697310 \| sarcoidosis C2364133 \| infection C2364108 \| stigma C2364072 \| depression C2364051 \| fatigue C2318511 \| nonalcoholic steatohepatitis C2242505 \| oral psoriasis C2186532 \| liver disease C2062979 \| spontaneous bacterial peritonitis C2004456 \| macronodular cirrhosis C1963823 \| hyperlipasemia C1963279 \| viral hepatitis C1963274 \| vasculitis C1963179 \| nausea C1963178 \| myelitis C1963154 \| renal failure C1963064 \| anxiety C1962972 \| proteinuria C1962971 \| myocarditis C1962966 \| retinopathy C1956391 \| temporal arteritis C1868683 \| b-cell chronic lymphocytic leukemia C1839611 \| n syndrome C1800706 \| idiopathic pulmonary fibrosis C1744558 \| t-cell deficiency C1737225 \| mesangioproliferative glomerulonephritis C1704430 \| urinary schistosomiasis C1695985 \| lewis-sumner syndrome C1623038 \| cirrhosis C1516669 \| clonal evolution C1512411 \| hepatocellular carcinoma C1512409 \| liver carcinogenesis C1510472 \| drug addiction C1504439 \| reversible posterior leukoencephalopathy syndrome C1421374 \| porphyria cutanea tarda C1398810 \| glomerulopathy C1373218 \| immunosuppression C1336820 \| treatment-induced anemia C1333969 \| hepatic leiomyosarcoma C1318520 \| necrotizing vasculitis C1318484 \| chimera C1304408 \| urticarial vasculitis C1292753 \| primary effusion lymphoma C1275974 \| splenic hamartoma C1269683 \| major depressive disorder C1269683 \| major depression C1264606 \| persistent infection C1136085 \| monoclonal gammopathies C1112746 \| primary hepatic lymphoma C1112746 \| liver lymphoma C1000483 \| anemia C0948120 \| hepatic siderosis C0920350 \| autoimmune thyroiditis C0917798 \| cerebral ischemia C0861876 \| recurrent hepatocellular carcinoma C0860197 \| advanced chronic liver disease C0858681 \| vitiligo vulgaris C0850666 \| helicobacter pylori infection C0745744 \| end stage liver disease C0744421 \| immune complex glomerulonephritis C0740343 \| mononeuropathy multiplex C0730345 \| microalbuminuria C0700201 \| sleep disturbance C0685201 \| splenic hemangioma C0679466 \| cognitive deficits C0599921 \| mucosa-associated lymphoid tissue C0598766 \| lymphomagenesis C0549473 \| thyroid cancer C0543697 \| mixed cryoglobulinemia C0543697 \| mixed cryoglobulinaemia C0521173 \| granulomatosis C0520463 \| chronic active hepatitis C0473221 \| cryoglobulinemic glomerulonephritis C0442874 \| neuropathy C0438692 \| vaginal discharge C0427008 \| stiffness C0406378 \| erosive oral lichen planus C0398650 \| immune thrombocytopenic purpura C0393819 \| chronic inflammatory demyelinating polyneuropathy C0392674 \| exhaustion C0349529 \| gastric carcinoid tumor C0348754 \| hepatotoxicity C0348024 \| thyroid dysfunction C0345905 \| intrahepatic cholangiocarcinoma C0345904 \| liver cancers C0345904 \| liver cancer C0343752 \| acute hiv infection C0343208 \| essential mixed cryoglobulinemia C0341714 \| renal lymphoma C0341439 \| chronic liver disease C0340992 \| cryoglobulinemic vasculitis C0339505 \| branch retinal vein occlusion C0276687 \| disseminated cryptococcosis C0276623 \| chronic viral hepatitis C0275518 \| acute infection C0272293 \| chronic idiopathic thrombocytopenic purpura C0272286 \| immune thrombocytopenia C0268749 \| fibrillary glomerulonephritis C0268731 \| glomerular diseases C0268731 \| glomerular disease C0268318 \| cholestasis of pregnancy C0267812 \| micronodular cirrhosis C0242647 \| malt lymphomas C0242584 \| autoimmune thrombocytopenia C0241910 \| autoimmune hepatitis C0240225 \| hepatic mass C0239946 \| liver fibrosis C0239946 \| hepatic fibrosis C0235950 \| zinc deficiency C0233401 \| psychiatric symptoms C0221239 \| rapidly progressive glomerulonephritis C0221207 \| cold urticaria C0206139 \| oral lichen planus C0178468 \| autoimmune thyroid disease C0162839 \| porokeratosis C0162557 \| acute liver failure C0162323 \| polyarthritis C0155773 \| portal vein thrombosis C0155773 \| portal thrombosis C0152025 \| polyneuropathy C0151825 \| skeletal pain C0151436 \| leukocytoclastic vasculitis C0151436 \| leucocytoclastic vasculitis C0151436 \| cutaneous leukocytoclastic vasculitis C0151317 \| chronic infection C0149904 \| cholestatic hepatitis C0086981 \| sicca syndrome C0085684 \| foot drop C0085605 \| liver failure C0085605 \| hepatic failure C0085253 \| adult still's disease C0085119 \| foot ulcers C0079744 \| diffuse large b-cell lymphoma C0079731 \| b-cell non-hodgkin's lymphoma C0079731 \| b-cell lymphomas C0079731 \| b-cell lymphoma C0079731 \| b cell lymphoma C0062527 \| hepatitis b C0042769 \| virus infection C0042769 \| viral infections C0042749 \| viremia C0042749 \| viraemia C0042345 \| varices C0041834 \| erythema C0040188 \| tic disorders C0040128 \| thyroid disorders C0040034 \| thrombocytopenia C0039841 \| thiamine deficiency C0038826 \| superinfection C0037274 \| skin disorders C0037274 \| skin diseases C0037274 \| cutaneous disorders C0037140 \| b virus infection C0037023 \| sialoadenitis C0036416 \| scleritis C0036161 \| o variant C0035435 \| rheumatic disease C0033860 \| psoriasis C0033774 \| pruritus C0032962 \| pregnancy complications C0031542 \| phlebitis C0031117 \| peripheral neuropathy C0031117 \| peripheral neuropathies C0031036 \| polyarteritis nodosa C0031036 \| panarteritis nodosa C0030920 \| peptic ulcer disease C0028258 \| nodular vasculitis C0024620 \| primary liver cancer C0024314 \| lymphoproliferative disorders C0024305 \| non-hodgkin's lymphoma C0024299 \| malignant lymphoma C0024299 \| lymphomas C0024299 \| lymphoma C0024141 \| systemic lupus erythematosus C0023903 \| hepatoma C0023895 \| liver diseases C0023895 \| hepatic disease C0023890 \| liver cirrhosis C0023646 \| lichen planus C0023530 \| leucopenia C0023434 \| chronic lymphocytic leukemia C0022658 \| renal diseases C0022658 \| renal disease C0022658 \| kidney diseases C0022116 \| ischaemia C0021308 \| infarction C0021053 \| immunological diseases C0021053 \| immunological disease C0021053 \| immune disorders C0020541 \| portal hypertension C0019829 \| hodgkin's lymphomas C0019250 \| congenital afibrinogenaemia C0019204 \| hepatocellular carcinomas C0019189 \| recurrent hepatitis C0019189 \| chronic hepatitis C0019080 \| hemorrhage C0018939 \| hematologic disorders C0018801 \| heart failure C0017665 \| membranous nephropathy C0017665 \| membranous glomerulonephritis C0017662 \| membranoproliferative glomerulonephritis C0017661 \| iga nephropathy C0017658 \| glomerulonephritis C0017658 \| glomerulonephritides C0016053 \| fibromyalgia C0015695 \| fatty liver C0014867 \| oesophageal varices C0014867 \| esophageal varices C0014130 \| endocrinopathy C0014059 \| acute disseminated encephalomyelitis C0014009 \| empyema C0011860 \| type ii diabetes mellitus C0011860 \| type 2 diabetes mellitus C0011860 \| type 2 diabetes C0011860 \| diabetes C0011849 \| diabetes mellitus C0010823 \| cytomegalovirus infection C0010403 \| cryoglobulinemia C0010403 \| cryoglobulinaemia C0010266 \| cranial neuropathy C0010043 \| corneal ulceration C0008370 \| cholestasis C0007193 \| dilated cardiomyopathy C0007137 \| squamous cell carcinoma C0004623 \| bacterial infections C0004610 \| bacteremia C0004364 \| autoimmune disorders C0004364 \| autoimmune diseases C0004364 \| autoimmune disease C0002878 \| haemolytic anaemia C0000737 \| abdominal pain
Text Mined Symptom	UMLS \| Name \| Sentences' Count(Total Symptoms:122) C0009450 \| infection \| 498 C0023890 \| cirrhosis \| 146 C0151317 \| chronic infection \| 129 C0019204 \| hepatocellular carcinoma \| 119 C0239946 \| liver fibrosis \| 98 C0023895 \| liver disease \| 86 C0239946 \| hepatic fibrosis \| 40 C0021311 \| infections \| 36 C0023890 \| liver cirrhosis \| 31 C0019163 \| hepatitis b \| 31 C0011570 \| depression \| 30 C0040034 \| thrombocytopenia \| 27 C0011847 \| diabetes \| 26 C0019189 \| chronic hepatitis \| 26 C0010403 \| cryoglobulinemia \| 22 C1264606 \| persistent infection \| 20 C0042384 \| vasculitis \| 19 C0015672 \| fatigue \| 16 C2711227 \| hepatic steatosis \| 15 C0002871 \| anemia \| 15 C0341439 \| chronic liver disease \| 14 C0024299 \| lymphoma \| 13 C0022658 \| renal disease \| 12 C0033860 \| psoriasis \| 10 C0011849 \| diabetes mellitus \| 9 C0543697 \| mixed cryoglobulinemia \| 9 C0340992 \| cryoglobulinemic vasculitis \| 8 C0085605 \| liver failure \| 8 C0023646 \| lichen planus \| 8 C0042769 \| virus infection \| 8 C0023903 \| liver cancer \| 8 C2711227 \| liver steatosis \| 7 C0021079 \| immunosuppression \| 7 C0442874 \| neuropathy \| 7 C0079744 \| diffuse large b-cell lymphoma \| 6 C0037140 \| b virus infection \| 6 C0017658 \| glomerulonephritis \| 6 C0348024 \| thyroid dysfunction \| 6 C0042721 \| viral hepatitis \| 6 C0079731 \| b-cell lymphoma \| 6 C0036202 \| sarcoidosis \| 6 C0042749 \| viremia \| 6 C0206139 \| oral lichen planus \| 5 C0427008 \| stiffness \| 5 C0011860 \| type 2 diabetes \| 5 C0042345 \| varices \| 5 C0037317 \| sleep disturbance \| 5 C0024314 \| lymphoproliferative disorders \| 5 C0033687 \| proteinuria \| 4 C0019204 \| hepatoma \| 4 C0241910 \| autoimmune hepatitis \| 4 C0020541 \| portal hypertension \| 4 C0920350 \| autoimmune thyroiditis \| 4 C0041834 \| erythema \| 3 C0031036 \| polyarteritis nodosa \| 3 C0008370 \| cholestasis \| 3 C0035078 \| renal failure \| 3 C0035309 \| retinopathy \| 3 C0014867 \| esophageal varices \| 3 C0023434 \| chronic lymphocytic leukemia \| 3 C0023895 \| liver diseases \| 3 C0235378 \| hepatotoxicity \| 3 C0024305 \| non-hodgkin's lymphoma \| 3 C0017661 \| iga nephropathy \| 3 C0543697 \| mixed cryoglobulinaemia \| 3 C0015695 \| fatty liver \| 3 C0014867 \| oesophageal varices \| 3 C0010403 \| cryoglobulinaemia \| 3 C0017662 \| membranoproliferative glomerulonephritis \| 2 C0031117 \| peripheral neuropathy \| 2 C0040128 \| thyroid disorders \| 2 C0026975 \| myelitis \| 2 C0272286 \| immune thrombocytopenia \| 2 C0038826 \| superinfection \| 2 C0392674 \| exhaustion \| 2 C0004364 \| autoimmune disease \| 2 C0011860 \| type 2 diabetes mellitus \| 2 C0085605 \| hepatic failure \| 2 C0024299 \| lymphomas \| 2 C0019204 \| hepatocellular carcinomas \| 2 C0162557 \| acute liver failure \| 2 C0003467 \| anxiety \| 2 C0149904 \| cholestatic hepatitis \| 2 C0233401 \| psychiatric symptoms \| 1 C0268318 \| cholestasis of pregnancy \| 1 C0345905 \| intrahepatic cholangiocarcinoma \| 1 C0022658 \| kidney diseases \| 1 C0036416 \| scleritis \| 1 C0275518 \| acute infection \| 1 C0037274 \| skin disorders \| 1 C0521173 \| granulomatosis \| 1 C0021308 \| infarction \| 1 C0085684 \| foot drop \| 1 C1510472 \| drug addiction \| 1 C0016053 \| fibromyalgia \| 1 C0022658 \| renal diseases \| 1 C0019189 \| recurrent hepatitis \| 1 C0004623 \| bacterial infections \| 1 C0041696 \| major depressive disorder \| 1 C0014059 \| acute disseminated encephalomyelitis \| 1 C0033774 \| pruritus \| 1 C0268731 \| glomerular diseases \| 1 C0019080 \| hemorrhage \| 1 C0004364 \| autoimmune diseases \| 1 C0473221 \| cryoglobulinemic glomerulonephritis \| 1 C0679466 \| cognitive deficits \| 1 C0598766 \| lymphomagenesis \| 1 C0023895 \| hepatic disease \| 1 C1136085 \| monoclonal gammopathies \| 1 C0042769 \| viral infections \| 1 C0086981 \| sicca syndrome \| 1 C0393626 \| opsoclonus-myoclonus syndrome \| 1 C0010823 \| cytomegalovirus infection \| 1 C0041696 \| major depression \| 1 C0014130 \| endocrinopathy \| 1 C0850666 \| helicobacter pylori infection \| 1 C0277787 \| stigma \| 1 C0007137 \| squamous cell carcinoma \| 1 C1398810 \| glomerulopathy \| 1 C1112746 \| primary hepatic lymphoma \| 1 C0079731 \| b-cell lymphomas \| 1 C0037274 \| skin diseases \| 1

Manually Genotype(Total Text Mining Genotypes:0)
(Waiting for update.)

All Snps(Total Genotypes:180)
snpId	pubmedId	geneId	geneSymbol	diseaseId	sourceId	sentence	score	Year	geneSymbol_dbSNP	CHROMOSOME	POS	REF	ALT
rs1063478	25528575	3112	HLA-DOB	umls:C0019196	BeFree	HLA-DMA rs1063478, HLA-DOA rs2284191, and HLA-DOB rs7383287 were identified as novel loci in Chinese population that were involved in HCV infection.	0.000271442	2014	HLA-DMA	6	32949767	C	T
rs1063478	25528575	3108	HLA-DMA	umls:C0019196	BeFree	HLA-DMA rs1063478 and HLA-DOA rs2284191 were independent factors of acquiring HCV infection.	0.000271442	2014	HLA-DMA	6	32949767	C	T
rs1063478	25528575	3111	HLA-DOA	umls:C0019196	BeFree	HLA-DMA rs1063478 and HLA-DOA rs2284191 were independent factors of acquiring HCV infection.	0.000271442	2014	HLA-DMA	6	32949767	C	T
rs10853728	21254157	9975	NR1D2	umls:C0019196	BeFree	Because the first three SNPs were in very strong linkage disequilibrium with one another (r2 = 0.94-0.96), rs8099917 and rs10853728 were selected for an analysis of their influence on the achievement of rapid virological response [RVR; seronegativity for hepatitis C virus (HCV) RNA in treatment week 4] and sustained virological response (SVR; seronegativity for HCV RNA throughout 24 weeks of posttreatment follow-up).	0.000814326	2011	NA	19	39254506	C	G,T
rs1127354	21246582	5047	PAEP	umls:C0019196	BeFree	Triple therapy for 12 weeks, followed by PEG-IFN and RBV for 12 weeks, was given to 49 patients with RBV-sensitive (CC at rs1127354) and 12 with RBV-resistant (CA/AA) ITPA genotypes who had been infected with hepatitis C virus (HCV) of genotype 1.	0.030672932	2011	ITPA	20	3213196	C	A,G,T
rs1127354	21246582	3447	IFNA13	umls:C0019196	BeFree	Triple therapy for 12 weeks, followed by PEG-IFN and RBV for 12 weeks, was given to 49 patients with RBV-sensitive (CC at rs1127354) and 12 with RBV-resistant (CA/AA) ITPA genotypes who had been infected with hepatitis C virus (HCV) of genotype 1.	0.03040149	2011	ITPA	20	3213196	C	A,G,T
rs11881222	24696021	282617	IFNL3	umls:C0019196	BeFree	This study demonstrated that Indonesian patients with chronic hepatitis C (mostly ethnic Java people) mostly were infected with hepatitis C virus (HCV) genotype 1; however, they carried mainly the major genotypes of interleukin 28B (IL-28B) single nucleotide polymorphisms (SNPs) (rs12979860 CC, rs11881222 TT, rs8103142 AA, and rs8099917 TT), and they mostly achieved sustained virological responses to pegylated interferon/ribavirin treatment.	0.22048837	2015	IFNL3	19	39244283	A	G
rs11881222	23135173	282617	IFNL3	umls:C0019196	BeFree	To estimate the impact of interleukin 28B (IL28B) polymorphisms (rs12980275, rs8099917, rs7248668, and rs11881222) and their haplotypes on hepatitis C virus (HCV) treatment (peg-interferon-α and ribavirin) success in 324 HIV/HCV-coinfected patients.	0.22048837	2013	IFNL3	19	39244283	A	G
rs129679860	23147144	282617	IFNL3	umls:C0019196	BeFree	A single nucleotide polymorphism, rs129679860, in the IL28B locus is associated with the viral kinetics and a sustained virological response in a chronic, monoinfected hepatitis C virus genotype-1 Brazilian population treated with pegylated interferon-ribavirin.	0.22048837	2012	NA	NA	NA	NA	NA
rs1297860	24707497	282617	IFNL3	umls:C0019196	BeFree	Conversely, patients with lymphoproliferative disorders had not any significantly different IL28B rs1297860 allelic distribution than those with chronic HCV, but, like all chronic HCV-related diseases, they showed a lower CC frequency than patients who spontaneously cleared HCV.	0.22048837	2013	NA	NA	NA	NA	NA
rs12979860	24724563	101180976	IFNL4	umls:C0019196	BeFree	Interferon-λ4-related dinucleotide variant rs368234815 TT/-G is strongly linked with rs12979860 polymorphism, the most important genetic marker connected to treatment-induced hepatitis C virus clearance.	0.005428837	2014	IFNL3;IFNL4	19	39248147	C	T
rs12979860	24465773	282617	IFNL3	umls:C0019196	BeFree	Comparative analysis of rs12979860 SNP of the IFNL3 gene in children with hepatitis C and ethnic matched controls using 1000 Genomes Project data.	0.22048837	2013	IFNL3;IFNL4	19	39248147	C	T
rs12979860	21112660	282617	IFNL3	umls:C0019196	BeFree	Common IL28B locus polymorphisms (SNPs rs8099917 and rs12979860) have been reported to affect peg-interferon plus ribavirin combination therapy (PEG-RBV) for hepatitis C virus (HCV) genotype 1b, but few reports have examined their effect on other two common genotypes, 2a and 2b.	0.22048837	2011	IFNL3;IFNL4	19	39248147	C	T
rs12979860	25703417	282617	IFNL3	umls:C0019196	BeFree	In conclusion, HCV genotypes and IL28B rs12979860 are predictive markers for the efficiency of interferon plus ribavirin combinational therapy of HCV infection.	0.22048837	2014	IFNL3;IFNL4	19	39248147	C	T
rs12979860	21147186	282617	IFNL3	umls:C0019196	BeFree	Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection.	0.22048837	2011	IFNL3;IFNL4	19	39248147	C	T
rs12979860	24072198	101180976	IFNL4	umls:C0019196	BeFree	IFNL4 ss469415590 variant is a better predictor than rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfected patients.	0.005428837	2014	IFNL3;IFNL4	19	39248147	C	T
rs12979860	25462177	282617	IFNL3	umls:C0019196	BeFree	Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.	0.22048837	2014	IFNL3;IFNL4	19	39248147	C	T
rs12979860	21112660	5047	PAEP	umls:C0019196	BeFree	Common IL28B locus polymorphisms (SNPs rs8099917 and rs12979860) have been reported to affect peg-interferon plus ribavirin combination therapy (PEG-RBV) for hepatitis C virus (HCV) genotype 1b, but few reports have examined their effect on other two common genotypes, 2a and 2b.	0.030672932	2011	IFNL3;IFNL4	19	39248147	C	T
rs12979860	25225180	5047	PAEP	umls:C0019196	BeFree	The association of rs12979860 and rs8099917 single nucleotide polymorphisms (SNPs) near IL28B with sustained virological response (SVR) in hepatic allograft recipients undergoing treatment with PEGylated interferon (PEG-IFN) plus ribavirin (RBV) for recurrent hepatitis C virus (HCV) infection remains inconclusive.	0.030672932	2014	IFNL3;IFNL4	19	39248147	C	T
rs12979860	24776764	282617	IFNL3	umls:C0019196	BeFree	The interleukin 28B (IL28B) rs12979860 polymorphism is associated with treatment outcome in hepatitis C virus (HCV) genotype 1 and 4 patients.	0.22048837	2014	IFNL3;IFNL4	19	39248147	C	T
rs12979860	21606533	282617	IFNL3	umls:C0019196	BeFree	Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus.	0.22048837	2011	IFNL3;IFNL4	19	39248147	C	T
rs12979860	24792632	282617	IFNL3	umls:C0019196	BeFree	Interleukin 28B rs12979860 single-nucleotide polymorphism predicts spontaneous clearance of hepatitis C virus in children.	0.22048837	2014	IFNL3;IFNL4	19	39248147	C	T
rs12979860	21479134	282617	IFNL3	umls:C0019196	BeFree	IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection.	0.22048837	2011	IFNL3;IFNL4	19	39248147	C	T
rs12979860	23266640	282617	IFNL3	umls:C0019196	BeFree	Interleukin-28B rs12979860C/T and rs8099917T/G contribute to spontaneous clearance of hepatitis C virus in Caucasians.	0.22048837	2013	IFNL3;IFNL4	19	39248147	C	T
rs12979860	25658540	282617	IFNL3	umls:C0019196	BeFree	The IFNL4 ss469415590 polymorphism, in high linkage disequilibrium with the IL28B rs12979860 variant, has been associated with hepatitis C virus clearance.	0.22048837	2014	IFNL3;IFNL4	19	39248147	C	T
rs12979860	23219017	3586	IL10	umls:C0019196	BeFree	The aim of the study was to evaluate the association of of IL28B rs12979860, TGF-β1-509, TNF-α 308, and IL-10-1082 polymorphisms with the susceptibility to hepatitis C virus genotype 4 infection and response to pegylated interferon-α and ribavirin therapy.	0.042181906	2013	IFNL3;IFNL4	19	39248147	C	T
rs12979860	25504078	80339	PNPLA3	umls:C0019196	BeFree	Single nucleotide polymorphisms (SNPs) in the epidermal growth factor (EGF, rs4444903), patatin-like phospholipase domain-containing protein 3 (PNPLA3, rs738409) genes, and near the interleukin-28B (IL28B, rs12979860) gene are linked to treatment response, fibrosis, and hepatocellular carcinoma (HCC) in chronic hepatitis C. Whether these SNPs independently or in combination predict clinical deterioration in hepatitis C virus (HCV)-related cirrhosis is unknown.	0.002171535	2014	IFNL3;IFNL4	19	39248147	C	T
rs12979860	22986179	3565	IL4	umls:C0019196	BeFree	The G allele for IL-10 (-1082 A/G), the C allele for IL-4 (+3 C/T) and the C and T alleles for IL-28B (rs12979860 and rs8099917, respectively) are associated with spontaneous viral clearance in hepatitis C infection.	0.014364013	2012	IFNL3;IFNL4	19	39248147	C	T
rs12979860	21704279	282617	IFNL3	umls:C0019196	BeFree	Recent genome-wide association studies have identified two host single-nucleotide polymorphisms (SNPs) near the IL28B gene (rs12979860 C/T and rs8099917 T/G) that are associated with sustained virological response in patients infected with the hepatitis C virus.	0.22048837	2011	IFNL3;IFNL4	19	39248147	C	T
rs12979860	25658540	101180976	IFNL4	umls:C0019196	BeFree	The IFNL4 ss469415590 polymorphism, in high linkage disequilibrium with the IL28B rs12979860 variant, has been associated with hepatitis C virus clearance.	0.005428837	2014	IFNL3;IFNL4	19	39248147	C	T
rs12979860	22986179	3586	IL10	umls:C0019196	BeFree	The G allele for IL-10 (-1082 A/G), the C allele for IL-4 (+3 C/T) and the C and T alleles for IL-28B (rs12979860 and rs8099917, respectively) are associated with spontaneous viral clearance in hepatitis C infection.	0.042181906	2012	IFNL3;IFNL4	19	39248147	C	T
rs12979860	23936821	282617	IFNL3	umls:C0019196	BeFree	The rs12979860 CC genotype of the interleukin 28B (IL28B) polymorphism is associated with high rates of sustained virological response (SVR) to peginterferon (PegIFN) and ribavirin (Rbv) in hepatitis C virus genotype-1 (HCV-1) patients.	0.22048837	2013	IFNL3;IFNL4	19	39248147	C	T
rs12979860	25971683	282617	IFNL3	umls:C0019196	BeFree	Differential distribution of IL28B.rs12979860 single-nucleotide polymorphism among Egyptian healthcare workers with and without a hepatitis C virus-specific cellular immune response.	0.22048837	2015	IFNL3;IFNL4	19	39248147	C	T
rs12979860	21146242	282617	IFNL3	umls:C0019196	BeFree	A single nucleotide polymorphism (rs12979860 C/T) 3kb upstream of the interleukin 28B (IL-28B) gene was shown to be associated with hepatitis C clearance.	0.22048837	2011	IFNL3;IFNL4	19	39248147	C	T
rs12979860	23225905	282617	IFNL3	umls:C0019196	BeFree	The single-nucleotide polymorphism (SNP) rs12979860 near the IL28B gene has been associated with the spontaneous clearance of hepatitis C virus.	0.22048837	2013	IFNL3;IFNL4	19	39248147	C	T
rs12979860	24874053	282617	IFNL3	umls:C0019196	BeFree	Genetic variation of interleukin-28B (IL-28B) rs12979860 T/C polymorphism is associated with the immune response to interferon (IFN) therapy, which is applied in the treatment of chronic viral hepatitis induced by hepatitis B virus (HBV) and hepatitis C virus (HCV).	0.22048837	2014	IFNL3;IFNL4	19	39248147	C	T
rs12979860	24748394	101180976	IFNL4	umls:C0019196	BeFree	IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against Hepatitis C Virus genotype 1 or 4 in Caucasians.	0.005428837	2014	IFNL3;IFNL4	19	39248147	C	T
rs12979860	22664940	282617	IFNL3	umls:C0019196	BeFree	Spontaneous clearance of hepatitis C infection after liver transplantation from IL28B rs12979860 CC donors.	0.22048837	2012	IFNL3;IFNL4	19	39248147	C	T
rs12979860	23219017	282617	IFNL3	umls:C0019196	BeFree	The aim of the study was to evaluate the association of of IL28B rs12979860, TGF-β1-509, TNF-α 308, and IL-10-1082 polymorphisms with the susceptibility to hepatitis C virus genotype 4 infection and response to pegylated interferon-α and ribavirin therapy.	0.22048837	2013	IFNL3;IFNL4	19	39248147	C	T
rs12979860	24696021	282617	IFNL3	umls:C0019196	BeFree	This study demonstrated that Indonesian patients with chronic hepatitis C (mostly ethnic Java people) mostly were infected with hepatitis C virus (HCV) genotype 1; however, they carried mainly the major genotypes of interleukin 28B (IL-28B) single nucleotide polymorphisms (SNPs) (rs12979860 CC, rs11881222 TT, rs8103142 AA, and rs8099917 TT), and they mostly achieved sustained virological responses to pegylated interferon/ribavirin treatment.	0.22048837	2015	IFNL3;IFNL4	19	39248147	C	T
rs12979860	22013224	282617	IFNL3	umls:C0019196	BeFree	IL28B rs12979860 genotype and spontaneous clearance of hepatitis C virus in a multi-ethnic cohort of injection drug users: evidence for a supra-additive association.	0.22048837	2011	IFNL3;IFNL4	19	39248147	C	T
rs12979860	25204264	282617	IFNL3	umls:C0019196	BeFree	The patient had the IL-28B gene polymorphism rs12979860 CT genotype, which is associated not only with antiviral therapy response but also with diabetes risk after liver transplantation for hepatitis C.	0.22048837	2014	IFNL3;IFNL4	19	39248147	C	T
rs12979860	22239156	282617	IFNL3	umls:C0019196	BeFree	rs12979860 in interleukin 28B (IL28B) gene is associated with response to interferon-α therapy and natural viral clearance in hepatitis C. The role of this polymorphism is less known in hepatitis B virus (HBV) infection.	0.22048837	2012	IFNL3;IFNL4	19	39248147	C	T
rs12979860	23880623	282617	IFNL3	umls:C0019196	BeFree	Single-nucleotide polymorphisms (SNPs) in the IL-10 gene (-1082 [rs1800896], -819 [rs3021097], and -592 [rs1800872]) and the IL-28B gene (rs12979860) in adults were shown to be associated with hepatitis C virus (HCV) clearance.	0.22048837	2014	IFNL3;IFNL4	19	39248147	C	T
rs12979860	25897598	282617	IFNL3	umls:C0019196	BeFree	The interleukin-28B (IL28B) gene contains a single-nucleotide polymorphism at location rs12979860 that affects both the natural history of hepatitis C virus infection and the patient's response to treatment, particularly interferon-based regimens with or without protease inhibitors.	0.22048837	2015	IFNL3;IFNL4	19	39248147	C	T
rs12979860	25420838	282617	IFNL3	umls:C0019196	BeFree	CC genotype at rs12979860 of IL28B is associated with lower risk of new-onset diabetes after transplantation in adult patients with liver transplantation for hepatitis C cirrhosis.	0.22048837	2015	IFNL3;IFNL4	19	39248147	C	T
rs12979860	22298465	282617	IFNL3	umls:C0019196	BeFree	Early viral load and recipient interleukin-28B rs12979860 genotype are predictors of the progression of hepatitis C after liver transplantation.	0.22048837	2012	IFNL3;IFNL4	19	39248147	C	T
rs12979860	22257210	282617	IFNL3	umls:C0019196	BeFree	Two single nucleotide polymorphisms (SNP, rs8099917, rs12979860) near the IL28B gene have been illustrated as outcome predictors of hepatitis C virus (HCV) treatment with pegylated interferon/ribavirin.	0.22048837	2012	IFNL3;IFNL4	19	39248147	C	T
rs12979860	24748394	282617	IFNL3	umls:C0019196	BeFree	The rs12979860 variant, linked to IL28B gene, predicts sustained viral response (SVR) to pegylated-interferon/ribavirin (pegIFN/RBV) therapy in Hepatitis C Virus genotype 1 or 4 (HCV-1/4)-infected patients.	0.22048837	2014	IFNL3;IFNL4	19	39248147	C	T
rs12979860	21703201	282617	IFNL3	umls:C0019196	BeFree	Here, we investigated the relative genetic contributions of the CCR5Δ32 deletion and the IL28B rs12979860 polymorphisms to spontaneous clearance of hepatitis C in a single-source outbreak.	0.22048837	2011	IFNL3;IFNL4	19	39248147	C	T
rs12979860	23784926	282617	IFNL3	umls:C0019196	BeFree	The correlation between IL28B.rs12979860 genotypes and CMI is suggestive of a possible important role of CMI in favoring hepatitis C virus clearance in CC patients.	0.22048837	2014	IFNL3;IFNL4	19	39248147	C	T
rs12979860	24387833	282617	IFNL3	umls:C0019196	BeFree	rs12979860 and rs8099917 interleukin-28B polymorphisms are associated with spontaneous or interferon-alpha induced hepatitis C clearance, CC and TT genotypes (respectively) being the most favourable.	0.22048837	2013	IFNL3;IFNL4	19	39248147	C	T
rs12979860	23880623	3586	IL10	umls:C0019196	BeFree	Single-nucleotide polymorphisms (SNPs) in the IL-10 gene (-1082 [rs1800896], -819 [rs3021097], and -592 [rs1800872]) and the IL-28B gene (rs12979860) in adults were shown to be associated with hepatitis C virus (HCV) clearance.	0.042181906	2014	IFNL3;IFNL4	19	39248147	C	T
rs12979860	21647799	282617	IFNL3	umls:C0019196	BeFree	This study aimed to determine whether the single-nucleotide polymorphism (rs12979860 C/T) of the interleukin 28B (IL-28B) gene, which is associated with hepatitis C virus (HCV) clearance, is also associated with fibrosis in chronic HCV infection.	0.22048837	2011	IFNL3;IFNL4	19	39248147	C	T
rs12979860	25504078	282617	IFNL3	umls:C0019196	BeFree	Single nucleotide polymorphisms (SNPs) in the epidermal growth factor (EGF, rs4444903), patatin-like phospholipase domain-containing protein 3 (PNPLA3, rs738409) genes, and near the interleukin-28B (IL28B, rs12979860) gene are linked to treatment response, fibrosis, and hepatocellular carcinoma (HCC) in chronic hepatitis C. Whether these SNPs independently or in combination predict clinical deterioration in hepatitis C virus (HCV)-related cirrhosis is unknown.	0.22048837	2014	IFNL3;IFNL4	19	39248147	C	T
rs12979860	22790387	282617	IFNL3	umls:C0019196	BeFree	Increased risk of severe hepatitis C virus recurrence after liver transplantation in patients with a T allele of IL28B rs12979860.	0.22048837	2012	IFNL3;IFNL4	19	39248147	C	T
rs12979860	25225180	282617	IFNL3	umls:C0019196	BeFree	The association of rs12979860 and rs8099917 single nucleotide polymorphisms (SNPs) near IL28B with sustained virological response (SVR) in hepatic allograft recipients undergoing treatment with PEGylated interferon (PEG-IFN) plus ribavirin (RBV) for recurrent hepatitis C virus (HCV) infection remains inconclusive.	0.22048837	2014	IFNL3;IFNL4	19	39248147	C	T
rs12979860	25504078	1950	EGF	umls:C0019196	BeFree	Single nucleotide polymorphisms (SNPs) in the epidermal growth factor (EGF, rs4444903), patatin-like phospholipase domain-containing protein 3 (PNPLA3, rs738409) genes, and near the interleukin-28B (IL28B, rs12979860) gene are linked to treatment response, fibrosis, and hepatocellular carcinoma (HCC) in chronic hepatitis C. Whether these SNPs independently or in combination predict clinical deterioration in hepatitis C virus (HCV)-related cirrhosis is unknown.	0.002909916	2014	IFNL3;IFNL4	19	39248147	C	T
rs12980275	25852288	282617	IFNL3	umls:C0019196	BeFree	IL28B rs12980275 AA genotype is a strong predictor of positive response to IFN therapy in Chinese Han patients with hepatitis C.	0.22048837	2015	NA	19	39241143	A	G
rs12980275	23135173	282617	IFNL3	umls:C0019196	BeFree	To estimate the impact of interleukin 28B (IL28B) polymorphisms (rs12980275, rs8099917, rs7248668, and rs11881222) and their haplotypes on hepatitis C virus (HCV) treatment (peg-interferon-α and ribavirin) success in 324 HIV/HCV-coinfected patients.	0.22048837	2013	NA	19	39241143	A	G
rs13181	19919686	2068	ERCC2	umls:C0019196	GAD	[XPD codon 751 polymorphism modifies the risk of hepatocellular carcinoma]	0.002638474	2009	ERCC2;KLC3	19	45351661	T	A,G
rs13266634	24499956	169026	SLC30A8	umls:C0019196	BeFree	SLC30A8 rs13266634 polymorphism is related to a favorable cardiometabolic lipid profile in HIV/hepatitis C virus-coinfected patients.	0.000271442	2015	SLC30A8;LOC105375716	8	117172544	C	T
rs1617640	25227310	2056	EPO	umls:C0019196	BeFree	Erythropoietin rs1617640 G allele associates with an attenuated rise of serum erythropoietin and a marked decline of hemoglobin in hepatitis C patients undergoing antiviral therapy.	0.001085767	2014	EPO	7	100719675	C	A
rs17401966	24204805	23095	KIF1B	umls:C0019196	BeFree	Genome-wide association studies (GWAS) have identified three loci (rs17401966 in KIF1B, rs7574865 in STAT4, rs9275319 in HLA-DQ) as being associated with hepatitis B virus-related hepatocellular carcinoma (HBV-related HCC) in a Chinese population, two loci (rs2596542 in MICA, rs9275572 located between HLA-DQA and HLA-DQB) with hepatitis C virus-related HCC (HCV-related HCC) in a Japanese population.	0.000271442	2013	KIF1B	1	10325413	A	G
rs17401966	24204805	6775	STAT4	umls:C0019196	BeFree	Genome-wide association studies (GWAS) have identified three loci (rs17401966 in KIF1B, rs7574865 in STAT4, rs9275319 in HLA-DQ) as being associated with hepatitis B virus-related hepatocellular carcinoma (HBV-related HCC) in a Chinese population, two loci (rs2596542 in MICA, rs9275572 located between HLA-DQA and HLA-DQB) with hepatitis C virus-related HCC (HCV-related HCC) in a Japanese population.	0.000271442	2013	KIF1B	1	10325413	A	G
rs17401966	24204805	3119	HLA-DQB1	umls:C0019196	BeFree	Genome-wide association studies (GWAS) have identified three loci (rs17401966 in KIF1B, rs7574865 in STAT4, rs9275319 in HLA-DQ) as being associated with hepatitis B virus-related hepatocellular carcinoma (HBV-related HCC) in a Chinese population, two loci (rs2596542 in MICA, rs9275572 located between HLA-DQA and HLA-DQB) with hepatitis C virus-related HCC (HCV-related HCC) in a Japanese population.	0.031671618	2013	KIF1B	1	10325413	A	G
rs17401966	24204805	84668	FAM126A	umls:C0019196	BeFree	Genome-wide association studies (GWAS) have identified three loci (rs17401966 in KIF1B, rs7574865 in STAT4, rs9275319 in HLA-DQ) as being associated with hepatitis B virus-related hepatocellular carcinoma (HBV-related HCC) in a Chinese population, two loci (rs2596542 in MICA, rs9275572 located between HLA-DQA and HLA-DQB) with hepatitis C virus-related HCC (HCV-related HCC) in a Japanese population.	0.003800186	2013	KIF1B	1	10325413	A	G
rs1799864	17465499	729230	CCR2	umls:C0019196	BeFree	CCL2-2518 A/G and CCR2 190 A/G do not influence the outcome of hepatitis C virus infection in the Spanish population.	0.001085767	2007	CCR2	3	46357717	G	A
rs1799864	15086398	729230	CCR2	umls:C0019196	BeFree	The G190A polymorphism (variant allele Ile64) in the first transmembrane domain of CCR2 was under-represented in the 29 patients who had cleared the hepatitis C virus spontaneously (P = 0.018).	0.001085767	2004	CCR2	3	46357717	G	A
rs1799864	17465499	6347	CCL2	umls:C0019196	BeFree	CCL2-2518 A/G and CCR2 190 A/G do not influence the outcome of hepatitis C virus infection in the Spanish population.	0.003724241	2007	CCR2	3	46357717	G	A
rs1799945	17160239	3077	HFE	umls:C0019196	BeFree	Mutation of the hemochromatosis gene (C282Y and/or H63D) was diagnosed in 16 (55.2%) patients with nonalcoholic steatohepatitis, in 12 (60%) patients with hepatitis C and in 8 (40%) patients with no liver disease.	0.161291635	2006	HFE	6	26090951	C	G
rs1799945	12673077	3077	HFE	umls:C0019196	BeFree	Porphyria cutanea tarda, C282Y, H63D and S65C HFE gene mutations and hepatitis C infection: a study from southern France.	0.161291635	2003	HFE	6	26090951	C	G
rs1799945	10692680	3077	HFE	umls:C0019196	BeFree	The recent identification of 2 mutations in the HFE gene related to hereditary haemochromatosis (Cys282Tyr and His63Asp) provided an opportunity to test whether they are associated with hepatic iron accumulation and the activity and severity of liver disease in hepatitis C virus (HCV) infection.	0.161291635	2000	HFE	6	26090951	C	G
rs1800206	16297361	5465	PPARA	umls:C0019196	BeFree	Peroxisome proliferator-activated receptor alpha L162V polymorphism in nonalcoholic steatohepatitis and genotype 1 hepatitis C virus-related liver steatosis.	0.00408156	2005	PPARA	22	46218377	C	G
rs1800562	17160239	3077	HFE	umls:C0019196	BeFree	Mutation of the hemochromatosis gene (C282Y and/or H63D) was diagnosed in 16 (55.2%) patients with nonalcoholic steatohepatitis, in 12 (60%) patients with hepatitis C and in 8 (40%) patients with no liver disease.	0.161291635	2006	HFE	6	26092913	G	A
rs1800562	12673077	3077	HFE	umls:C0019196	BeFree	Porphyria cutanea tarda, C282Y, H63D and S65C HFE gene mutations and hepatitis C infection: a study from southern France.	0.161291635	2003	HFE	6	26092913	G	A
rs1800562	10692680	3077	HFE	umls:C0019196	BeFree	The recent identification of 2 mutations in the HFE gene related to hereditary haemochromatosis (Cys282Tyr and His63Asp) provided an opportunity to test whether they are associated with hepatic iron accumulation and the activity and severity of liver disease in hepatitis C virus (HCV) infection.	0.161291635	2000	HFE	6	26092913	G	A
rs1800562	11079015	3077	HFE	umls:C0019196	BeFree	In this study we analyzed the livers of 50 transplant patients with a diagnosis of either hepatitis C cirrhosis or cryptogenic cirrhosis for the prevalence of the more common C282Y mutation of the HFE gene and correlated the findings to hepatic iron concentration.	0.161291635	2000	HFE	6	26092913	G	A
rs1800562	17062032	3077	HFE	umls:C0019196	BeFree	The prevalence of HFE C282Y gene mutation is increased in Spanish patients with porphyria cutanea tarda without hepatitis C virus infection.	0.161291635	2006	HFE	6	26092913	G	A
rs1800730	12673077	3077	HFE	umls:C0019196	BeFree	Porphyria cutanea tarda, C282Y, H63D and S65C HFE gene mutations and hepatitis C infection: a study from southern France.	0.161291635	2003	HFE	6	26090957	A	T
rs1800872	23880623	282617	IFNL3	umls:C0019196	BeFree	Single-nucleotide polymorphisms (SNPs) in the IL-10 gene (-1082 [rs1800896], -819 [rs3021097], and -592 [rs1800872]) and the IL-28B gene (rs12979860) in adults were shown to be associated with hepatitis C virus (HCV) clearance.	0.22048837	2014	IL10	1	206773062	T	G
rs1800872	23880623	3586	IL10	umls:C0019196	BeFree	Single-nucleotide polymorphisms (SNPs) in the IL-10 gene (-1082 [rs1800896], -819 [rs3021097], and -592 [rs1800872]) and the IL-28B gene (rs12979860) in adults were shown to be associated with hepatitis C virus (HCV) clearance.	0.042181906	2014	IL10	1	206773062	T	G
rs1800896	23880623	3586	IL10	umls:C0019196	BeFree	Single-nucleotide polymorphisms (SNPs) in the IL-10 gene (-1082 [rs1800896], -819 [rs3021097], and -592 [rs1800872]) and the IL-28B gene (rs12979860) in adults were shown to be associated with hepatitis C virus (HCV) clearance.	0.042181906	2014	IL10	1	206773552	T	C
rs1800896	23880623	282617	IFNL3	umls:C0019196	BeFree	Single-nucleotide polymorphisms (SNPs) in the IL-10 gene (-1082 [rs1800896], -819 [rs3021097], and -592 [rs1800872]) and the IL-28B gene (rs12979860) in adults were shown to be associated with hepatitis C virus (HCV) clearance.	0.22048837	2014	IL10	1	206773552	T	C
rs20575	22401174	8797	TNFRSF10A	umls:C0019196	BeFree	To determine if gene variants in the TRAIL receptor I (DR4) gene affect the risk of hepatitis C virus (HCV)-induced liver cancer (HCC), we analysed DR4 mutations C626G (rs20575) and A683C (rs20576) in HCV-infected patients with and without HCC.	0.000542884	2012	TNFRSF10A	8	23201811	C	G
rs20576	22401174	8797	TNFRSF10A	umls:C0019196	BeFree	To determine if gene variants in the TRAIL receptor I (DR4) gene affect the risk of hepatitis C virus (HCV)-induced liver cancer (HCC), we analysed DR4 mutations C626G (rs20575) and A683C (rs20576) in HCV-infected patients with and without HCC.	0.000542884	2012	TNFRSF10A	8	23200707	T	G
rs2069707	25798684	8797	TNFRSF10A	umls:C0019196	BeFree	In conclusion, genetic variation of TRAIL-R1 rs4242392 is linked with response to interferon-based therapy for HCV infection, and genetic variation IFN-γ rs2069707 is associated with natural clearance of HCV infection.	0.000542884	2016	IFNG	12	68160508	G	C
rs2069707	25798684	3458	IFNG	umls:C0019196	BeFree	In conclusion, genetic variation of TRAIL-R1 rs4242392 is linked with response to interferon-based therapy for HCV infection, and genetic variation IFN-γ rs2069707 is associated with natural clearance of HCV infection.	0.149346855	2016	IFNG	12	68160508	G	C
rs2284191	25528575	3111	HLA-DOA	umls:C0019196	BeFree	HLA-DMA rs1063478 and HLA-DOA rs2284191 were independent factors of acquiring HCV infection.	0.000271442	2014	HLA-DOA	6	33008877	G	A
rs2284191	25528575	3112	HLA-DOB	umls:C0019196	BeFree	HLA-DMA rs1063478, HLA-DOA rs2284191, and HLA-DOB rs7383287 were identified as novel loci in Chinese population that were involved in HCV infection.	0.000271442	2014	HLA-DOA	6	33008877	G	A
rs2284191	25528575	3108	HLA-DMA	umls:C0019196	BeFree	HLA-DMA rs1063478 and HLA-DOA rs2284191 were independent factors of acquiring HCV infection.	0.000271442	2014	HLA-DOA	6	33008877	G	A
rs2287622	21320040	8647	ABCB11	umls:C0019196	BeFree	A common variant of BSEP (p.V444A) is now a well-established susceptibility factor for acquired cholestasis and recent evidence suggests that the same variant also influences the therapeutic response and disease progression of viral hepatitis C. Studies in large independent cohorts are now needed to confirm the relevance of p.V444A.	0.000814326	2011	ABCB11	2	168973818	A	T,G,C
rs2305482	25515861	5047	PAEP	umls:C0019196	BeFree	Furthermore, rs2305482 genotype was associated with the doses of pegylated interferon (PEG-IFN) that could be tolerated in hepatitis C virus genotype 1-infected patients treated with PEG-IFN plus ribavirin, but not with treatment efficacy.	0.030672932	2014	PSMD3	17	39984674	A	C
rs2476601	19115939	26191	PTPN22	umls:C0019196	BeFree	PTPN22 C1858T polymorphism and the outcome of hepatitis C virus infection.	0.005362824	2008	PTPN22;AP4B1-AS1	1	113834946	A	G
rs2596542	23665287	100507436	MICA	umls:C0019196	BeFree	Recently, genetic variations in MICA (lead single nucleotide polymorphism [SNP] rs2596542) were identified by a genome-wide association study (GWAS) to be associated with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) in Japanese patients.	0.000814326	2013	MICA;LOC101929072	6	31398818	C	T
rs2596542	24204805	84668	FAM126A	umls:C0019196	BeFree	Genome-wide association studies (GWAS) have identified three loci (rs17401966 in KIF1B, rs7574865 in STAT4, rs9275319 in HLA-DQ) as being associated with hepatitis B virus-related hepatocellular carcinoma (HBV-related HCC) in a Chinese population, two loci (rs2596542 in MICA, rs9275572 located between HLA-DQA and HLA-DQB) with hepatitis C virus-related HCC (HCV-related HCC) in a Japanese population.	0.003800186	2013	MICA;LOC101929072	6	31398818	C	T
rs2596542	23024757	100507436	MICA	umls:C0019196	BeFree	We recently reported that a single nucleotide polymorphism (SNP) rs2596542 located in the MICA promoter region was significantly associated with the risk for hepatitis C virus (HCV)-induced hepatocellular carcinoma (HCC) and also with serum levels of soluble MICA (sMICA).	0.000814326	2012	MICA;LOC101929072	6	31398818	C	T
rs2596542	24204805	23095	KIF1B	umls:C0019196	BeFree	Genome-wide association studies (GWAS) have identified three loci (rs17401966 in KIF1B, rs7574865 in STAT4, rs9275319 in HLA-DQ) as being associated with hepatitis B virus-related hepatocellular carcinoma (HBV-related HCC) in a Chinese population, two loci (rs2596542 in MICA, rs9275572 located between HLA-DQA and HLA-DQB) with hepatitis C virus-related HCC (HCV-related HCC) in a Japanese population.	0.000271442	2013	MICA;LOC101929072	6	31398818	C	T
rs2596542	24204805	3119	HLA-DQB1	umls:C0019196	BeFree	Genome-wide association studies (GWAS) have identified three loci (rs17401966 in KIF1B, rs7574865 in STAT4, rs9275319 in HLA-DQ) as being associated with hepatitis B virus-related hepatocellular carcinoma (HBV-related HCC) in a Chinese population, two loci (rs2596542 in MICA, rs9275572 located between HLA-DQA and HLA-DQB) with hepatitis C virus-related HCC (HCV-related HCC) in a Japanese population.	0.031671618	2013	MICA;LOC101929072	6	31398818	C	T
rs2596542	24204805	6775	STAT4	umls:C0019196	BeFree	Genome-wide association studies (GWAS) have identified three loci (rs17401966 in KIF1B, rs7574865 in STAT4, rs9275319 in HLA-DQ) as being associated with hepatitis B virus-related hepatocellular carcinoma (HBV-related HCC) in a Chinese population, two loci (rs2596542 in MICA, rs9275572 located between HLA-DQA and HLA-DQB) with hepatitis C virus-related HCC (HCV-related HCC) in a Japanese population.	0.000271442	2013	MICA;LOC101929072	6	31398818	C	T
rs3017887	25888935	50507	NOX4	umls:C0019196	BeFree	One hundred seventy eight naïve HCV patients (49.3% male; 65% HCV genotype 1) with positive HCV RNA were genotyped using specific primers and fluorescent-labeled probes for SNPs rs3017887 in NOX4 and -675 T → A in CYBA.	0.000542884	2015	NOX4	11	89492920	A	C
rs3021097	23880623	282617	IFNL3	umls:C0019196	BeFree	Single-nucleotide polymorphisms (SNPs) in the IL-10 gene (-1082 [rs1800896], -819 [rs3021097], and -592 [rs1800872]) and the IL-28B gene (rs12979860) in adults were shown to be associated with hepatitis C virus (HCV) clearance.	0.22048837	2014	NA	NA	NA	NA	NA
rs3021097	23880623	3586	IL10	umls:C0019196	BeFree	Single-nucleotide polymorphisms (SNPs) in the IL-10 gene (-1082 [rs1800896], -819 [rs3021097], and -592 [rs1800872]) and the IL-28B gene (rs12979860) in adults were shown to be associated with hepatitis C virus (HCV) clearance.	0.042181906	2014	NA	NA	NA	NA	NA
rs35761398	23707465	1269	CNR2	umls:C0019196	BeFree	We investigated the effects of CNR2 rs35761398 in patients with hepatitis C virus (HCV) infection.	0.000271442	2013	NA	NA	NA	NA	NA
rs368234815	24724563	101180976	IFNL4	umls:C0019196	BeFree	Interferon-λ4-related dinucleotide variant rs368234815 TT/-G is strongly linked with rs12979860 polymorphism, the most important genetic marker connected to treatment-induced hepatitis C virus clearance.	0.005428837	2014	IFNL3;IFNL4	19	39248514	TT	G
rs3792323	19208361	7867	MAPKAPK3	umls:C0019196	BeFree	We identified 2 SNPs (rs3792323 [A/T] and rs616589 [G/A]), located in intron 2 of mitogen-activated protein kinase-activated protein kinase 3 (MAPKAPK3) that were associated with the outcome of IFN therapy in patients infected with hepatitis C virus (HCV) genotype 1b (P = 4.6 x 10(-5) and 4.8 x 10(-5), respectively).	0.000271442	2009	MAPKAPK3	3	50622900	A	T
rs386555427	22401174	8797	TNFRSF10A	umls:C0019196	BeFree	To determine if gene variants in the TRAIL receptor I (DR4) gene affect the risk of hepatitis C virus (HCV)-induced liver cancer (HCC), we analysed DR4 mutations C626G (rs20575) and A683C (rs20576) in HCV-infected patients with and without HCC.	0.000542884	2012	NA	NA	NA	NA	NA
rs386586050	21839239	7098	TLR3	umls:C0019196	BeFree	Toll-like receptor 3 L412F polymorphism may protect against acute graft rejection in adult patients undergoing liver transplantation for hepatitis C-related cirrhosis.	0.005895776	2011	NA	NA	NA	NA	NA
rs386596107	24882572	6648	SOD2	umls:C0019196	BeFree	The aim of the present study was to investigate the influence of MPO G-463A and SOD2 Ala16Val polymorphisms in the severity of liver fibrosis in individuals with chronic HCV infection.	0.005362824	2014	NA	NA	NA	NA	NA
rs4074	22173151	2919	CXCL1	umls:C0019196	BeFree	Enhanced production of CXCL1 in response to HCV antigens in carriers of the rs4074 A allele together with its increased frequency in cirrhotic patients with hepatitis C suggest the CXCL1 rs4074 A allele as a genetic risk factor for cirrhosis progression in hepatitis C.	0.000271442	2012	CXCL1	4	73870427	A	G
rs4242392	25798684	8797	TNFRSF10A	umls:C0019196	BeFree	In conclusion, genetic variation of TRAIL-R1 rs4242392 is linked with response to interferon-based therapy for HCV infection, and genetic variation IFN-γ rs2069707 is associated with natural clearance of HCV infection.	0.000542884	2016	TNFRSF10A	8	23204120	T	C
rs4242392	25798684	3458	IFNG	umls:C0019196	BeFree	In conclusion, genetic variation of TRAIL-R1 rs4242392 is linked with response to interferon-based therapy for HCV infection, and genetic variation IFN-γ rs2069707 is associated with natural clearance of HCV infection.	0.149346855	2016	TNFRSF10A	8	23204120	T	C
rs4444903	25504078	1950	EGF	umls:C0019196	BeFree	Single nucleotide polymorphisms (SNPs) in the epidermal growth factor (EGF, rs4444903), patatin-like phospholipase domain-containing protein 3 (PNPLA3, rs738409) genes, and near the interleukin-28B (IL28B, rs12979860) gene are linked to treatment response, fibrosis, and hepatocellular carcinoma (HCC) in chronic hepatitis C. Whether these SNPs independently or in combination predict clinical deterioration in hepatitis C virus (HCV)-related cirrhosis is unknown.	0.002909916	2014	EGF	4	109912954	A	G
rs4444903	25504078	80339	PNPLA3	umls:C0019196	BeFree	Single nucleotide polymorphisms (SNPs) in the epidermal growth factor (EGF, rs4444903), patatin-like phospholipase domain-containing protein 3 (PNPLA3, rs738409) genes, and near the interleukin-28B (IL28B, rs12979860) gene are linked to treatment response, fibrosis, and hepatocellular carcinoma (HCC) in chronic hepatitis C. Whether these SNPs independently or in combination predict clinical deterioration in hepatitis C virus (HCV)-related cirrhosis is unknown.	0.002171535	2014	EGF	4	109912954	A	G
rs4444903	25504078	282617	IFNL3	umls:C0019196	BeFree	Single nucleotide polymorphisms (SNPs) in the epidermal growth factor (EGF, rs4444903), patatin-like phospholipase domain-containing protein 3 (PNPLA3, rs738409) genes, and near the interleukin-28B (IL28B, rs12979860) gene are linked to treatment response, fibrosis, and hepatocellular carcinoma (HCC) in chronic hepatitis C. Whether these SNPs independently or in combination predict clinical deterioration in hepatitis C virus (HCV)-related cirrhosis is unknown.	0.22048837	2014	EGF	4	109912954	A	G
rs4804803	22061615	30835	CD209	umls:C0019196	BeFree	Previously the severity and outcome of dengue fever and hepatitis C (diseases caused by viruses from the family Flaviviridae) were associated with the rs4804803 single nucleotide polymorphism (SNP) located in the promoter region of the human CD209 gene.	0.005634266	2012	CD209	19	7747847	A	G
rs4880	24882572	6648	SOD2	umls:C0019196	BeFree	The aim of the present study was to investigate the influence of MPO G-463A and SOD2 Ala16Val polymorphisms in the severity of liver fibrosis in individuals with chronic HCV infection.	0.005362824	2014	SOD2	6	159692840	A	G
rs4986790	20400193	7099	TLR4	umls:C0019196	BeFree	The effect of TLR4 D299G on long-term graft survival was analyzed based on hepatitis C virus (HCV) serostatus.	0.004624443	2010	TLR4	9	117713024	A	G
rs4986790	20226000	7099	TLR4	umls:C0019196	BeFree	In a bivariate analysis several variables resulted significantly associated with active TB; intravenous drugs use (OR= 2.2; 95% CI [1.2-3.8]), hepatitis C virus (HCV) co-infection (OR= 3.4; 95% CI [1.6-7.1]), CD4 count (p<0.001), HIV viral load (p=0.003), latent TB prophylaxis (OR= 0.3; 95% CI [0.1-0.5]), and TLR4 Asp299Gly (OR= 2.0; 95% CI [1.1-4.2]).	0.004624443	2010	TLR4	9	117713024	A	G
rs4986938	25261585	2100	ESR2	umls:C0019196	BeFree	We provide here the first report that rs4986938 in the ESR2 gene played a potential sex-specific role in the etiology of HCV infection in a high-risk Chinese Han population, suggesting that ESR2 is a candidate susceptibility gene for HCV infection and viral clearance.	0.000271442	2014	ESR2	14	64233098	C	T
rs5443	16019105	2784	GNB3	umls:C0019196	BeFree	GNB3 C825T polymorphism and response to interferon-alfa/ribavirin treatment in patients with hepatitis C virus genotype 1 (HCV-1) infection.	0.005005506	2005	GNB3;CDCA3	12	6845711	C	T
rs5743708	20090572	7097	TLR2	umls:C0019196	BeFree	R753Q single-nucleotide polymorphism impairs toll-like receptor 2 recognition of hepatitis C virus core and nonstructural 3 proteins.	0.00680591	2010	TLR2	4	153705165	G	A
rs616589	19208361	7867	MAPKAPK3	umls:C0019196	BeFree	We identified 2 SNPs (rs3792323 [A/T] and rs616589 [G/A]), located in intron 2 of mitogen-activated protein kinase-activated protein kinase 3 (MAPKAPK3) that were associated with the outcome of IFN therapy in patients infected with hepatitis C virus (HCV) genotype 1b (P = 4.6 x 10(-5) and 4.8 x 10(-5), respectively).	0.000271442	2009	MAPKAPK3	3	50626198	A	G
rs7080536	19105210	3026	HABP2	umls:C0019196	BeFree	The Marburg I variant (G534E) of the factor VII-activating protease determines liver fibrosis in hepatitis C infection by reduced proteolysis of platelet-derived growth factor BB.	0.002638474	2009	HABP2	10	113588287	G	A
rs72258881	24910341	282617	IFNL3	umls:C0019196	BeFree	A nationwide, multi-center prospective study in Japan determined IL28B (rs8099917) genotype, (TA)n of rs72258881, and amino acid substitutions of hepatitis C virus and used these for multivariate analysis together with other parameters at pretreatment.	0.22048837	2014	NA	NA	NA	NA	NA
rs7248668	23135173	282617	IFNL3	umls:C0019196	BeFree	To estimate the impact of interleukin 28B (IL28B) polymorphisms (rs12980275, rs8099917, rs7248668, and rs11881222) and their haplotypes on hepatitis C virus (HCV) treatment (peg-interferon-α and ribavirin) success in 324 HIV/HCV-coinfected patients.	0.22048837	2013	NA	19	39253181	G	A
rs7383287	25528575	3112	HLA-DOB	umls:C0019196	BeFree	HLA-DMA rs1063478, HLA-DOA rs2284191, and HLA-DOB rs7383287 were identified as novel loci in Chinese population that were involved in HCV infection.	0.000271442	2014	HLA-DOB	6	32815309	A	G
rs738409	24269995	80339	PNPLA3	umls:C0019196	BeFree	We have assessed whether the PNPLA3 rs738409 (I148M) polymorphism may also affect the resolution and/or the progression of hepatitis C in a Moroccan cohort.	0.002171535	2013	PNPLA3	22	43928847	C	G
rs738409	25801076	80339	PNPLA3	umls:C0019196	BeFree	PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C.	0.002171535	2015	PNPLA3	22	43928847	C	G
rs738409	25504078	282617	IFNL3	umls:C0019196	BeFree	Single nucleotide polymorphisms (SNPs) in the epidermal growth factor (EGF, rs4444903), patatin-like phospholipase domain-containing protein 3 (PNPLA3, rs738409) genes, and near the interleukin-28B (IL28B, rs12979860) gene are linked to treatment response, fibrosis, and hepatocellular carcinoma (HCC) in chronic hepatitis C. Whether these SNPs independently or in combination predict clinical deterioration in hepatitis C virus (HCV)-related cirrhosis is unknown.	0.22048837	2014	PNPLA3	22	43928847	C	G
rs738409	24123231	80339	PNPLA3	umls:C0019196	BeFree	Donor PNPLA3 rs738409 genotype affects fibrosis progression in liver transplantation for hepatitis C.	0.002171535	2013	PNPLA3	22	43928847	C	G
rs738409	25504078	80339	PNPLA3	umls:C0019196	BeFree	Single nucleotide polymorphisms (SNPs) in the epidermal growth factor (EGF, rs4444903), patatin-like phospholipase domain-containing protein 3 (PNPLA3, rs738409) genes, and near the interleukin-28B (IL28B, rs12979860) gene are linked to treatment response, fibrosis, and hepatocellular carcinoma (HCC) in chronic hepatitis C. Whether these SNPs independently or in combination predict clinical deterioration in hepatitis C virus (HCV)-related cirrhosis is unknown.	0.002171535	2014	PNPLA3	22	43928847	C	G
rs738409	24927606	80339	PNPLA3	umls:C0019196	BeFree	PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C.	0.002171535	2015	PNPLA3	22	43928847	C	G
rs738409	25504078	1950	EGF	umls:C0019196	BeFree	Single nucleotide polymorphisms (SNPs) in the epidermal growth factor (EGF, rs4444903), patatin-like phospholipase domain-containing protein 3 (PNPLA3, rs738409) genes, and near the interleukin-28B (IL28B, rs12979860) gene are linked to treatment response, fibrosis, and hepatocellular carcinoma (HCC) in chronic hepatitis C. Whether these SNPs independently or in combination predict clinical deterioration in hepatitis C virus (HCV)-related cirrhosis is unknown.	0.002909916	2014	PNPLA3	22	43928847	C	G
rs738409	24927606	282617	IFNL3	umls:C0019196	BeFree	PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C.	0.22048837	2015	PNPLA3	22	43928847	C	G
rs738409	22087248	80339	PNPLA3	umls:C0019196	BeFree	The PNPLA3 rs738409 148M/M genotype is a risk factor for liver cancer in alcoholic cirrhosis but shows no or weak association in hepatitis C cirrhosis.	0.002171535	2011	PNPLA3	22	43928847	C	G
rs7574865	24204805	84668	FAM126A	umls:C0019196	BeFree	Genome-wide association studies (GWAS) have identified three loci (rs17401966 in KIF1B, rs7574865 in STAT4, rs9275319 in HLA-DQ) as being associated with hepatitis B virus-related hepatocellular carcinoma (HBV-related HCC) in a Chinese population, two loci (rs2596542 in MICA, rs9275572 located between HLA-DQA and HLA-DQB) with hepatitis C virus-related HCC (HCV-related HCC) in a Japanese population.	0.003800186	2013	STAT4	2	191099907	T	G
rs7574865	24204805	3119	HLA-DQB1	umls:C0019196	BeFree	Genome-wide association studies (GWAS) have identified three loci (rs17401966 in KIF1B, rs7574865 in STAT4, rs9275319 in HLA-DQ) as being associated with hepatitis B virus-related hepatocellular carcinoma (HBV-related HCC) in a Chinese population, two loci (rs2596542 in MICA, rs9275572 located between HLA-DQA and HLA-DQB) with hepatitis C virus-related HCC (HCV-related HCC) in a Japanese population.	0.031671618	2013	STAT4	2	191099907	T	G
rs7574865	24204805	6775	STAT4	umls:C0019196	BeFree	Genome-wide association studies (GWAS) have identified three loci (rs17401966 in KIF1B, rs7574865 in STAT4, rs9275319 in HLA-DQ) as being associated with hepatitis B virus-related hepatocellular carcinoma (HBV-related HCC) in a Chinese population, two loci (rs2596542 in MICA, rs9275572 located between HLA-DQA and HLA-DQB) with hepatitis C virus-related HCC (HCV-related HCC) in a Japanese population.	0.000271442	2013	STAT4	2	191099907	T	G
rs7574865	24204805	23095	KIF1B	umls:C0019196	BeFree	Genome-wide association studies (GWAS) have identified three loci (rs17401966 in KIF1B, rs7574865 in STAT4, rs9275319 in HLA-DQ) as being associated with hepatitis B virus-related hepatocellular carcinoma (HBV-related HCC) in a Chinese population, two loci (rs2596542 in MICA, rs9275572 located between HLA-DQA and HLA-DQB) with hepatitis C virus-related HCC (HCV-related HCC) in a Japanese population.	0.000271442	2013	STAT4	2	191099907	T	G
rs7903146	25353718	6934	TCF7L2	umls:C0019196	BeFree	rs7903146 polymorphism at transcription factor 7 like 2 gene is associated with total cholesterol and lipoprotein profile in HIV/hepatitis C virus-coinfected patients.	0.000271442	2015	TCF7L2	10	112998590	C	T
rs8099917	25462177	282617	IFNL3	umls:C0019196	BeFree	Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.	0.22048837	2014	NA	19	39252525	T	G
rs8099917	21048934	282617	IFNL3	umls:C0019196	GAD	[IL28B SNP rs8099917 is strongly associated with pegylated interferon-I+- and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients.]	0.22048837	2010	NA	19	39252525	T	G
rs8099917	24599320	282617	IFNL3	umls:C0019196	BeFree	Impact of donor and recipient single nucleotide polymorphisms of IL28B rs8099917 in living donor liver transplantation for hepatitis C.	0.22048837	2014	NA	19	39252525	T	G
rs8099917	22257210	282617	IFNL3	umls:C0019196	BeFree	Two single nucleotide polymorphisms (SNP, rs8099917, rs12979860) near the IL28B gene have been illustrated as outcome predictors of hepatitis C virus (HCV) treatment with pegylated interferon/ribavirin.	0.22048837	2012	NA	19	39252525	T	G
rs8099917	21879313	282617	IFNL3	umls:C0019196	BeFree	Genotype rs8099917 near the IL28B gene and amino acid substitution at position 70 in the core region of the hepatitis C virus are determinants of serum apolipoprotein B-100 concentration in chronic hepatitis C.	0.22048837	2012	NA	19	39252525	T	G
rs8099917	22095536	282617	IFNL3	umls:C0019196	BeFree	A total of 272 patients infected with hepatitis C virus (HCV) genotype 1b were grouped according to genetic polymorphisms near the IL28B gene (rs8099917).	0.22048837	2012	NA	19	39252525	T	G
rs8099917	20060832	282617	IFNL3	umls:C0019196	GAD	[The association of the IL28B locus with natural and treatment-associated control of HCV indicates the importance of innate immunity and interferon lambda in the pathogenesis of HCV infection.]	0.22048837	2010	NA	19	39252525	T	G
rs8099917	25225180	5047	PAEP	umls:C0019196	BeFree	The association of rs12979860 and rs8099917 single nucleotide polymorphisms (SNPs) near IL28B with sustained virological response (SVR) in hepatic allograft recipients undergoing treatment with PEGylated interferon (PEG-IFN) plus ribavirin (RBV) for recurrent hepatitis C virus (HCV) infection remains inconclusive.	0.030672932	2014	NA	19	39252525	T	G
rs8099917	21254157	9975	NR1D2	umls:C0019196	BeFree	Because the first three SNPs were in very strong linkage disequilibrium with one another (r2 = 0.94-0.96), rs8099917 and rs10853728 were selected for an analysis of their influence on the achievement of rapid virological response [RVR; seronegativity for hepatitis C virus (HCV) RNA in treatment week 4] and sustained virological response (SVR; seronegativity for HCV RNA throughout 24 weeks of posttreatment follow-up).	0.000814326	2011	NA	19	39252525	T	G
rs8099917	22387386	282617	IFNL3	umls:C0019196	BeFree	Predicting sustained viral response to hepatitis C using a rapid and simple IL28B rs8099917 genotyping assay.	0.22048837	2012	NA	19	39252525	T	G
rs8099917	20803561	282617	IFNL3	umls:C0019196	GAD	[Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection.]	0.22048837	2010	NA	19	39252525	T	G
rs8099917	24396987	282617	IFNL3	umls:C0019196	BeFree	Rs12979860 and rs8099917 single nucleotide polymorphisms of interleukin-28B gene: simultaneous genotyping in caucasian patients infected with hepatitis C virus.	0.22048837	2014	NA	19	39252525	T	G
rs8099917	22387386	57498	KIDINS220	umls:C0019196	BeFree	We established the use of tetra-primer amplification refractory mutation system polymerase chain reaction (ARMS-PCR) for detecting IL28B rs8099917 genotype (T>G) in 56 Chinese chronic hepatitis C patients infected with Hepatitis C Virus (HCV) genotype 1.	0.000542884	2012	NA	19	39252525	T	G
rs8099917	23266640	282617	IFNL3	umls:C0019196	BeFree	Interleukin-28B rs12979860C/T and rs8099917T/G contribute to spontaneous clearance of hepatitis C virus in Caucasians.	0.22048837	2013	NA	19	39252525	T	G
rs8099917	24696021	282617	IFNL3	umls:C0019196	BeFree	This study demonstrated that Indonesian patients with chronic hepatitis C (mostly ethnic Java people) mostly were infected with hepatitis C virus (HCV) genotype 1; however, they carried mainly the major genotypes of interleukin 28B (IL-28B) single nucleotide polymorphisms (SNPs) (rs12979860 CC, rs11881222 TT, rs8103142 AA, and rs8099917 TT), and they mostly achieved sustained virological responses to pegylated interferon/ribavirin treatment.	0.22048837	2015	NA	19	39252525	T	G
rs8099917	22986179	3586	IL10	umls:C0019196	BeFree	The G allele for IL-10 (-1082 A/G), the C allele for IL-4 (+3 C/T) and the C and T alleles for IL-28B (rs12979860 and rs8099917, respectively) are associated with spontaneous viral clearance in hepatitis C infection.	0.042181906	2012	NA	19	39252525	T	G
rs8099917	24910341	282617	IFNL3	umls:C0019196	BeFree	A nationwide, multi-center prospective study in Japan determined IL28B (rs8099917) genotype, (TA)n of rs72258881, and amino acid substitutions of hepatitis C virus and used these for multivariate analysis together with other parameters at pretreatment.	0.22048837	2014	NA	19	39252525	T	G
rs8099917	22156487	3447	IFNA13	umls:C0019196	BeFree	The rs8099917 genotype and total PEG-IFN dose were associated with SVR in patients with hepatitis C virus genotype 1.	0.03040149	2011	NA	19	39252525	T	G
rs8099917	21112660	282617	IFNL3	umls:C0019196	BeFree	Common IL28B locus polymorphisms (SNPs rs8099917 and rs12979860) have been reported to affect peg-interferon plus ribavirin combination therapy (PEG-RBV) for hepatitis C virus (HCV) genotype 1b, but few reports have examined their effect on other two common genotypes, 2a and 2b.	0.22048837	2011	NA	19	39252525	T	G
rs8099917	22156487	5047	PAEP	umls:C0019196	BeFree	The rs8099917 genotype and total PEG-IFN dose were associated with SVR in patients with hepatitis C virus genotype 1.	0.030672932	2011	NA	19	39252525	T	G
rs8099917	21704279	282617	IFNL3	umls:C0019196	BeFree	Recent genome-wide association studies have identified two host single-nucleotide polymorphisms (SNPs) near the IL28B gene (rs12979860 C/T and rs8099917 T/G) that are associated with sustained virological response in patients infected with the hepatitis C virus.	0.22048837	2011	NA	19	39252525	T	G
rs8099917	21112660	5047	PAEP	umls:C0019196	BeFree	Common IL28B locus polymorphisms (SNPs rs8099917 and rs12979860) have been reported to affect peg-interferon plus ribavirin combination therapy (PEG-RBV) for hepatitis C virus (HCV) genotype 1b, but few reports have examined their effect on other two common genotypes, 2a and 2b.	0.030672932	2011	NA	19	39252525	T	G
rs8099917	23135173	282617	IFNL3	umls:C0019196	BeFree	To estimate the impact of interleukin 28B (IL28B) polymorphisms (rs12980275, rs8099917, rs7248668, and rs11881222) and their haplotypes on hepatitis C virus (HCV) treatment (peg-interferon-α and ribavirin) success in 324 HIV/HCV-coinfected patients.	0.22048837	2013	NA	19	39252525	T	G
rs8099917	21879313	338	APOB	umls:C0019196	BeFree	Genotype rs8099917 near the IL28B gene and amino acid substitution at position 70 in the core region of the hepatitis C virus are determinants of serum apolipoprotein B-100 concentration in chronic hepatitis C.	0.002171535	2012	NA	19	39252525	T	G
rs8099917	24387833	282617	IFNL3	umls:C0019196	BeFree	rs12979860 and rs8099917 interleukin-28B polymorphisms are associated with spontaneous or interferon-alpha induced hepatitis C clearance, CC and TT genotypes (respectively) being the most favourable.	0.22048837	2013	NA	19	39252525	T	G
rs8099917	22986179	3565	IL4	umls:C0019196	BeFree	The G allele for IL-10 (-1082 A/G), the C allele for IL-4 (+3 C/T) and the C and T alleles for IL-28B (rs12979860 and rs8099917, respectively) are associated with spontaneous viral clearance in hepatitis C infection.	0.014364013	2012	NA	19	39252525	T	G
rs8099917	25225180	282617	IFNL3	umls:C0019196	BeFree	The association of rs12979860 and rs8099917 single nucleotide polymorphisms (SNPs) near IL28B with sustained virological response (SVR) in hepatic allograft recipients undergoing treatment with PEGylated interferon (PEG-IFN) plus ribavirin (RBV) for recurrent hepatitis C virus (HCV) infection remains inconclusive.	0.22048837	2014	NA	19	39252525	T	G
rs8103142	24696021	282617	IFNL3	umls:C0019196	BeFree	This study demonstrated that Indonesian patients with chronic hepatitis C (mostly ethnic Java people) mostly were infected with hepatitis C virus (HCV) genotype 1; however, they carried mainly the major genotypes of interleukin 28B (IL-28B) single nucleotide polymorphisms (SNPs) (rs12979860 CC, rs11881222 TT, rs8103142 AA, and rs8099917 TT), and they mostly achieved sustained virological responses to pegylated interferon/ribavirin treatment.	0.22048837	2015	IFNL3	19	39244466	T	C
rs868	25502482	7046	TGFBR1	umls:C0019196	BeFree	Association of 49245A>G (rs868) polymorphism in the 3'UTR of donor TGFBR1 gene with course of hepatitis C following orthotopic liver transplantation.	0.000271442	2015	TGFBR1	9	99149374	A	G
rs9275319	24204805	23095	KIF1B	umls:C0019196	BeFree	Genome-wide association studies (GWAS) have identified three loci (rs17401966 in KIF1B, rs7574865 in STAT4, rs9275319 in HLA-DQ) as being associated with hepatitis B virus-related hepatocellular carcinoma (HBV-related HCC) in a Chinese population, two loci (rs2596542 in MICA, rs9275572 located between HLA-DQA and HLA-DQB) with hepatitis C virus-related HCC (HCV-related HCC) in a Japanese population.	0.000271442	2013	NA	6	32698518	A	G
rs9275319	24204805	84668	FAM126A	umls:C0019196	BeFree	Genome-wide association studies (GWAS) have identified three loci (rs17401966 in KIF1B, rs7574865 in STAT4, rs9275319 in HLA-DQ) as being associated with hepatitis B virus-related hepatocellular carcinoma (HBV-related HCC) in a Chinese population, two loci (rs2596542 in MICA, rs9275572 located between HLA-DQA and HLA-DQB) with hepatitis C virus-related HCC (HCV-related HCC) in a Japanese population.	0.003800186	2013	NA	6	32698518	A	G
rs9275319	24204805	3119	HLA-DQB1	umls:C0019196	BeFree	Genome-wide association studies (GWAS) have identified three loci (rs17401966 in KIF1B, rs7574865 in STAT4, rs9275319 in HLA-DQ) as being associated with hepatitis B virus-related hepatocellular carcinoma (HBV-related HCC) in a Chinese population, two loci (rs2596542 in MICA, rs9275572 located between HLA-DQA and HLA-DQB) with hepatitis C virus-related HCC (HCV-related HCC) in a Japanese population.	0.031671618	2013	NA	6	32698518	A	G
rs9275319	24204805	6775	STAT4	umls:C0019196	BeFree	Genome-wide association studies (GWAS) have identified three loci (rs17401966 in KIF1B, rs7574865 in STAT4, rs9275319 in HLA-DQ) as being associated with hepatitis B virus-related hepatocellular carcinoma (HBV-related HCC) in a Chinese population, two loci (rs2596542 in MICA, rs9275572 located between HLA-DQA and HLA-DQB) with hepatitis C virus-related HCC (HCV-related HCC) in a Japanese population.	0.000271442	2013	NA	6	32698518	A	G
rs9275572	24204805	6775	STAT4	umls:C0019196	BeFree	Genome-wide association studies (GWAS) have identified three loci (rs17401966 in KIF1B, rs7574865 in STAT4, rs9275319 in HLA-DQ) as being associated with hepatitis B virus-related hepatocellular carcinoma (HBV-related HCC) in a Chinese population, two loci (rs2596542 in MICA, rs9275572 located between HLA-DQA and HLA-DQB) with hepatitis C virus-related HCC (HCV-related HCC) in a Japanese population.	0.000271442	2013	NA	6	32711222	A	G
rs9275572	24204805	23095	KIF1B	umls:C0019196	BeFree	Genome-wide association studies (GWAS) have identified three loci (rs17401966 in KIF1B, rs7574865 in STAT4, rs9275319 in HLA-DQ) as being associated with hepatitis B virus-related hepatocellular carcinoma (HBV-related HCC) in a Chinese population, two loci (rs2596542 in MICA, rs9275572 located between HLA-DQA and HLA-DQB) with hepatitis C virus-related HCC (HCV-related HCC) in a Japanese population.	0.000271442	2013	NA	6	32711222	A	G
rs9275572	24204805	84668	FAM126A	umls:C0019196	BeFree	Genome-wide association studies (GWAS) have identified three loci (rs17401966 in KIF1B, rs7574865 in STAT4, rs9275319 in HLA-DQ) as being associated with hepatitis B virus-related hepatocellular carcinoma (HBV-related HCC) in a Chinese population, two loci (rs2596542 in MICA, rs9275572 located between HLA-DQA and HLA-DQB) with hepatitis C virus-related HCC (HCV-related HCC) in a Japanese population.	0.003800186	2013	NA	6	32711222	A	G
rs9275572	24204805	3119	HLA-DQB1	umls:C0019196	BeFree	Genome-wide association studies (GWAS) have identified three loci (rs17401966 in KIF1B, rs7574865 in STAT4, rs9275319 in HLA-DQ) as being associated with hepatitis B virus-related hepatocellular carcinoma (HBV-related HCC) in a Chinese population, two loci (rs2596542 in MICA, rs9275572 located between HLA-DQA and HLA-DQB) with hepatitis C virus-related HCC (HCV-related HCC) in a Japanese population.	0.031671618	2013	NA	6	32711222	A	G
rs9400317	19684573	221264	AK9	umls:C0019196	GAD	[Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.]	0.002367032	2009	AK9	6	109686444	A	G
rs9514828	25800158	10673	TNFSF13B	umls:C0019196	BeFree	Association of BAFF -871C/T Promoter Polymorphism with Hepatitis C-Related Mixed Cryoglobulinemia in a Cohort of Egyptian Patients.	0.000542884	2016	TNFSF13B	13	108269025	C	T

GWASdb Annotation(Total Genotypes:0)
(Waiting for update.)

GWASdb Snp Trait(Total Genotypes:53)
CHR	POS	SNPID	REF	ALT	ORI_SNPID	PMID	P_VALUE	P_VALUE_TEXT	OR/BETA	CI95_TEXT	GWAS_INITIAL_SAMPLE_SIZE	SUB_POPULATION	SUPER_POPULATION	GWAS_TRAIT	HPO_ID	HPO_TERM	DO_ID	DO_TERM	MESH_ID	MESH_TERM	EFO_ID	EFO_TERM	DOLITE_TERM	RISK_ALLELE	PUBLICATION_TYPE	AA	GENE_SYMBOL	TYPE	REFGENE
1	120180034	rs347905	A	G	rs347905	21725309	8.11E-05	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	A	ZNF697
1	164922847	rs1419067	G	A	rs1419067	21725309	7.74E-05	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	T	NA
2	75459144	rs7568535	T	C	rs7568535	21725309	9.89E-05	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	C	NA
4	62004333	rs930668	A	G	rs930668	21725309	9.97E-06	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	G	NA
4	70979385	rs6855744	G	A	rs6855744	21725309	5.24E-05	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	A	NA
4	149002841	rs3733421	T	C	rs3733421	21725309	4.85E-05	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	A	NR3C2
5	31514127	rs17409275	C	T	rs17409275	21725309	1.19E-05	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	C	DROSHA
5	36632611	rs3776568	G	C	rs3776568	21725309	9.44E-05	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	G	SLC1A3
5	36636816	rs432268	A	G	rs432268	21725309	2.70E-05	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	A	SLC1A3
6	32678597	rs4273729	C	G	rs4273729	23420232	5.00E-17	NA	1.59	NA	1,482 chronic HCV patients; 919 spontaneously cleared HCV patients	NOPOP(2401)	ALL(2401)	NOPOP(2401)	ALL(2401)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	rs4273729	Multicenter Study	Research Support, N.I.H., Extramural	G
6	32678999	rs9275572	A	G	rs9275572	24376798	4.00E-16	NA	1.27	[1.19-1.33]	481 Japanese ancestry cases; 2,963 Japanese ancestry controls	Japanese(3444)	ALL(3444)	ASN(3444)	ALL(3444)	Chronic hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	rs9275572-T	Research Support, Non-U.S. Gov't	G	NA
6	32961361	rs9500927	G	A	rs9500927	21725309	8.61E-05	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	G	NA
7	8362456	rs10239677	G	A	rs10239677	21725309	5.63E-05	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	A	LOC100505938
7	40727223	rs6965055	T	G	rs6965055	21725309	2.66E-05	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	G	C7orf10
7	40728610	rs10486813	G	T	rs10486813	21725309	3.22E-05	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	T	C7orf10
7	40733756	rs6462987	C	T	rs6462987	21725309	2.73E-05	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	C	C7orf10
7	97389030	rs10085387	A	G	rs10085387	21725309	4.15E-05	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	A	NA
7	106055504	rs2893638	A	G	rs2893638	21725309	9.46E-05	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	G	NA
7	146049748	rs10225674	A	C,G	rs10225674	21725309	7.77E-05	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	A	CNTNAP2
7	151697032	rs11765654	G	A	rs11765654	21725309	7.46E-05	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	G	GALNTL5
9	87308783	rs1187343	G	A	rs1187343	21725309	6.03E-05	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	T	NTRK2
10	132491701	rs2939924	C	T	rs2939924	21725309	3.20E-05	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	A	NA
11	98850459	rs901541	A	G	rs901541	21725309	2.16E-05	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	T	NA
11	132469865	rs2437825	A	G	rs2437825	21725309	5.48E-05	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	T	OPCML
11	132492426	rs4936173	C	T	rs4936173	21725309	2.33E-05	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	T	OPCML
11	132581927	rs3016500	T	C	rs3016500	21725309	5.50E-05	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	T	OPCML
16	12625171	rs169773	G	T	rs169773	21725309	1.72E-05	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	T	SNX29
16	12625395	rs1794304	G	A	rs1794304	21725309	3.58E-06	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	A	SNX29
16	84304674	rs244844	T	C	rs244844	21725309	7.14E-05	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	T	NA
17	13451829	rs10521226	T	C	rs10521226	21725309	1.08E-05	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	C	HS3ST3A1
19	33909851	rs8182579	C	T	rs8182579	21725309	9.75E-05	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	C	PEPD
19	33914944	rs4362488	A	G	rs4362488	21725309	9.53E-05	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	G	PEPD
19	39731783	rs12980275	A	G	rs12980275	22497812	5.00E-17	NA	NA	NA	1,017 European ancestry cases; 207 African American ancestry cases; 95 Hispanic cases	African American(207)	European(1017)	Hispanic(95)	ALL(1319)	HIS(95)	AFR(207)	EUR(1017)	ALL(1319)	Lipid levels in hepatitis C treatment	HPOID:0003119	HPOID:0012115	Abnormality of lipid metabolism	Hepatitis	DOID:1883	hepatitis C	D006526	Hepatitis C	EFOID:0004220
19	39738787	rs12979860	C	T	rs12979860	23420232	2.00E-30	NA	2.2	NA	1,482 chronic HCV patients; 919 spontaneously cleared HCV patients	NOPOP(2401)	ALL(2401)	NOPOP(2401)	ALL(2401)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Multicenter Study	Research Support, N.I.H., Extramural	T
19	39743165	rs8099917	T	G	rs8099917	20060832	6.00E-09	NA	2.31	[1.74-3.06]	1,015 Swiss chronic HCV patients; 347 Swiss spontaneously cleared HCV patients	Swiss(1362)	ALL(1362)	EUR(1362)	ALL(1362)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	rs8099917-G	Research Support, Non-U.S. Gov't	T	NA
19	40097690	rs17795657	C	T	rs17795657	21725309	2.96E-05	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	C	LGALS13
20	3193842	rs1127354	C	A,G,T	rs1127354	20173735	2.00E-58	NA	NA	NA	988 European American cases; 198 African American cases; 100 Hispanic cases	African American(198)	Hispanic(100)	European American(988)	ALL(1286)	HIS(100)	AFR(198)	EUR(988)	ALL(1286)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C
20	3193893	rs7270101	A	C	rs7270101	20173735	9.00E-76	NA	NA	NA	988 European American cases; 198 African American cases; 100 Hispanic cases	African American(198)	Hispanic(100)	European American(988)	ALL(1286)	HIS(100)	AFR(198)	EUR(988)	ALL(1286)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C
22	32240721	rs7287054	A	G	rs7287054	21725309	3.80E-06	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	G	DEPDC5
22	32263131	rs470072	C	T	rs470072	21725309	8.67E-05	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	C	DEPDC5
22	32263162	rs5998152	T	C	rs5998152	21725309	1.19E-07	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	C	DEPDC5
22	32265903	rs1012068	T	G	rs1012068	21725309	1.00E-13	NA	1.75	[1.51-2.03]	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	rs1012068-G	Comparative Study	C	DEPDC5
22	32268400	rs737084	A	G	rs737084	21725309	5.93E-06	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	A	DEPDC5
22	32275353	rs5994443	T	C	rs5994443	21725309	5.26E-04	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	C,T	DEPDC5
22	32304179	rs5994449	T	A	rs5994449	21725309	1.31E-05	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	A	NA
22	32308680	rs16989636	T	C	rs16989636	21725309	1.39E-05	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	T	NA
22	32311619	rs4820994	A	G	rs4820994	21725309	2.99E-06	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	G	NA
22	32312842	rs5753816	T	C	rs5753816	21725309	4.90E-06	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	C	NA
22	32313933	rs5753818	C	T	rs5753818	21725309	9.43E-06	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	T	NA
22	32322384	rs11703779	T	C	rs11703779	21725309	4.16E-06	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	C	NA
22	32323511	rs5994451	T	G	rs5994451	21725309	1.15E-05	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	G	NA
22	32324030	rs4820996	A	G	rs4820996	21725309	4.16E-06	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	A,G	NA
22	32326021	rs2015580	C	T	rs2015580	21725309	9.19E-05	NA	NA	NA	212 Japanese ancestry cases; 765 Japanese ancestry controls	Japanese(977)	ALL(977)	ASN(977)	ALL(977)	Chronic Hepatitis C infection	HPOID:0200123	Chronic hepatitis	DOID:1883	hepatitis C	D019698	Hepatitis C, Chronic	EFOID:0004220	chronic hepatitis C infection	Hepatitis C	NA	Comparative Study	T	NA

Mapped by lexical matching(Total Items:0)
(Waiting for update.)

Mapped by homologous gene(Total Items:0)
(Waiting for update.)

Chemical(Total Drugs:13)
CUI	ChemicalName	ChemicalID	CasRN	DiseaseName	DiseaseID	DirectEvidence	PubMedIDs
C0019196	cyclosporine	D016572	59865-13-3	hepatitis c	MESH:D006526	marker/mechanism	16182838
C0019196	cyclosporine	D016572	59865-13-3	hepatitis c	MESH:D006526	therapeutic	17420205
C0019196	morphine	D009020	57-27-2	hepatitis c	MESH:D006526	marker/mechanism	12937158
C0019196	nelfinavir	D019888	159989-64-7	hepatitis c	MESH:D006526	therapeutic	11519908
C0019196	peginterferon alfa-2a	C100416	-	hepatitis c	MESH:D006526	marker/mechanism	16182838
C0019196	peginterferon alfa-2a	C100416	-	hepatitis c	MESH:D006526	therapeutic	15371138
C0019196	peginterferon alfa-2b	C417083	-	hepatitis c	MESH:D006526	therapeutic	12897097
C0019196	ribavirin	D012254	36791-04-5	hepatitis c	MESH:D006526	marker/mechanism	16182838
C0019196	ribavirin	D012254	36791-04-5	hepatitis c	MESH:D006526	therapeutic	10083207
C0019196	sofosbuvir	D000069474	-	hepatitis c	MESH:D006526	therapeutic	25850880
C0019196	tacrolimus	D016559	109581-93-3	hepatitis c	MESH:D006526	marker/mechanism	9636597
C0019196	vitamin e	D014810	1406-18-4	hepatitis c	MESH:D006526	marker/mechanism	17420205
C0019196	zidovudine	D015215	30516-87-1	hepatitis c	MESH:D006526	therapeutic	11519908

FDA approved drug and dosage information(Total Drugs:6)
DiseaseID	Drug_name	active_ingredients	strength	Dosage Form/Route	Marketing Status	TE code	RLD	RS
MESH:D006526	retrovir	zidovudine	100MG	CAPSULE;ORAL	Prescription	AB	Yes	Yes
MESH:D006526	retrovir	zidovudine	50MG/5ML	SYRUP;ORAL	Prescription	AA	Yes	Yes
MESH:D006526	retrovir	zidovudine	10MG/ML	INJECTABLE;INJECTION	Prescription	AP	Yes	Yes
MESH:D006526	retrovir	zidovudine	200MG	TABLET;ORAL	Discontinued	None	No	No
MESH:D006526	zidovudine	zidovudine	60MG	TABLET;ORAL	Discontinued	None	No	No
MESH:D006526	zidovudine	zidovudine	60MG	TABLET;ORAL	Discontinued	None	No	No

FDA labeling changes(Total Drugs:6)
DiseaseID	Pediatric_Labeling_Date	Trade_Name	Generic_Name_or_Proper_Name	Indications Studied	Label Changes Summary	Product Labeling	BPCA(B)	PREA(P)	BPCA(B) and PREA(P)	Pediatric Rule (R)	Sponsor	Pediatric Exclusivity Granted Date	NNPS
MESH:D006526	6/11/2009	retrovir	zidovudine	Treatment of HIV-1 infection in combination with other antiretroviral agents	Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg	Labeling	-	P	-	-	GlaxoSmithKline	-	TRUE'
MESH:D006526	6/11/2009	retrovir	zidovudine	Treatment of HIV-1 infection in combination with other antiretroviral agents	Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg	Labeling	-	P	-	-	GlaxoSmithKline	-	TRUE'
MESH:D006526	6/11/2009	retrovir	zidovudine	Treatment of HIV-1 infection in combination with other antiretroviral agents	Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg	Labeling	-	P	-	-	GlaxoSmithKline	-	TRUE'
MESH:D006526	6/11/2009	retrovir	zidovudine	Treatment of HIV-1 infection in combination with other antiretroviral agents	Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg	Labeling	-	P	-	-	GlaxoSmithKline	-	TRUE'
MESH:D006526	09/19/2008	retrovir syrup, capsules and tablets	zidovudine	Used in combination with 18 other antiretroviral agents for the treatment of HIV-1 infection	Dosing and administration information provided to children 6 weeks to less than 18 years of age Macrocytosis was reported in the majority of pediatric patients receiving Retrovir 180 mg/m2 every 6 hours in open-label studies New dosing regimen	Labeling	-	P	-	-	GlaxoSmithKline	-	TRUE'
MESH:D006526	6/11/2009	retrovir	zidovudine	Treatment of HIV-1 infection in combination with other antiretroviral agents	Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg	Labeling	-	P	-	-	GlaxoSmithKline	-	TRUE'